# Table of Contents

## GENERAL
- Welcome Address page 03
- Committees page 04
- Congress Organisation page 05
- Floorplans page 06
- Programme at a Glance page 08

## SCIENTIFIC PROGRAMME
- Scientific Programme – Wednesday, September 2 page 10
- Scientific Programme – Thursday, September 3 page 11
- Scientific Programme – Friday, September 4 page 16
- Scientific Programme – Saturday, September 5 page 20
- Poster Presentations:
  - Poster Topics P01 – P05 *(Part 1)*: Friday, September 4 page 25
  - Poster Topics P05 *(Part 2)*: Saturday, September 5 page 30

## INFORMATION
- Information for Presenters – Posters and Oral Presentations page 36
- Registration Fees page 38
- Networking Events page 39
- General Information page 40

## ANCILLARY PROGRAMME
- Satellite Symposia page 46

## SPONSORS & EXHIBITORS
- Sponsors & Exhibitors page 49
- Exhibiton Floorplan page 51
Welcome Address

WELCOME TO THE LUPUS 2015 CONGRESS IN VIENNA!

Dear Colleagues,

We cordially welcome you to Lupus 2015 and to the city of Vienna. The history of Lupus erythematosus is intimately associated with Medicine in this very city. It was here, at the times of the 2nd Viennese School of Medicine, where in 1845 Ferdinand von Hebra coined the metaphor of a butterfly for the lupus rash; it was here where in 1872 Moriz Kaposi described that Lupus erythematosus need not be confined to the skin but could be a systemic disease characterized by fever, anaemia and other organ manifestations; and it was here where in 1904 Donath and Landsteiner characterized the first ever autoantibody and the complement dependence of haemolytic anaemia.

Despite its long history, SLE has still not unravelled itself. The pathogenesis of the disease is still insufficiently known and the aetiology continues to be even more enigmatic. We do not yet understand which mechanisms underlie the different manifestations of the disease and how they interconnect, and so we are still not aware how many diseases the SLE “syndrome” comprises of and what their detailed characteristics and differences are. We still have difficulties in optimal assessment of the disease and definitions of populations for clinical trials. Consequently, therapy continues to be empiric in nature and its outcome unpredictable; and while targeted therapies have just begun to enter the field, we do not apprehend why one works and others not, because we are still far from understanding the nature of the disease. Despite all these limitations, the fate of SLE has never been better than today, though even more success is what we wish for our patients and especially predictability of therapeutic response, reduction of adverse events and comprehension of what we should do and why.

Major congresses allow presenting and discussing the latest developments in a field. To this end, the 11th International Congress on Systemic Lupus Erythematosus - Lupus 2015 offers a platform for elaborating on the most recent pathogenetic, diagnostic, biometric and therapeutic insights in SLE, to debate the assets and limitations within our discipline at this very point in time and to develop ideas on how to bring our area forward for the benefit of our patients. Almost 1000 scientists and clinicians, patients and health professionals from over 70 countries of the world gather here during this late summer week to enlighten each other and move the wheel of research and development forward to a speed that will allow breakthroughs as we have seen them in other areas of medicine in general and rheumatology in particular.

Aside from the science that the Congress will offer, the city of Vienna provides you with among the best in history and culture that you may find around the world. Some of the globe’s premier museums present dozens of exhibitions, and three Opera Houses and two huge concert halls with more than excellent acoustics and with the world’s best orchestras playing will entertain you with a unique repertoire. Strolling through the city, be it its Roman remnants, medieval portions, Renaissance buildings, Fin de Siècle marvels, modern architecture or splendid parks, will allow you grasping more than two thousand years of history, embraced by Beethoven, Mozart or Schönberg with their symphonies, concerts and breakthrough innovations; Schnitzler (Eyes wide shut), Salten (Bambi), Zweig (The world of yesterday) and many other famous authors; Wittgenstein, Schlick, Popper and Neurath and their philosophical colleagues of the Vienna Circle; Klimt, Schiele, Kokoschka and other prolific painters; Wagner, Loos, Hoffmann and other most influential architects and designers; Billroth and Freud…and, cycling back to Lupus: Hebra and Kaposi.

Last not least we would like to thank all of you and especially our speakers and chairpersons for coming to this 11th International Congress on SLE. We also gratefully acknowledge the support by the many sponsors listed at the back of the program and the staff for their great work! If there are any questions, please do not hesitate to get in touch with the staff or one of us.

We wish you a pleasant and successful meeting!

Josef Smolen and Georg Stummvoll
Committees

Organizing Committee

**President**
Josef Smolen

**Secretary**
Georg Stummvoll

Advisory Committee of Past Chairs

Mary Carmen Amigo, Mexico City (MX)
Shunle Chen, Shanghai (CN)
John Esdaile, Vancouver (CA)
Pao-Hsiii Feng, Singapore (SG)
Marvin Fritzler, Calgary (CA)
Graham R.V. Hughes, London (UK)
Munther A. Khamashta, London (UK)
Robert G. Lahita, New York (US)
Bernardo Pons-Estel, Rosario (AR)
Yehuda Shoenfeld, Jerusalem (IL)
Eng M. Tan, LaJolla (US)
Donato Alarcón-Segovia, Cancun (MX)

Scientific Committee

The local organizing committee

Kurt Derfler, Vienna
Winfried Graninger, Graz
Peter M. Heil, Vienna
Andreas Kronbichler, Innsbruck
Kurt Redlich, Vienna
Clemens Scheinecker, Vienna
Tanja Stamm, Vienna
Günter Steiner, Vienna
Christof Zimmermann, Vienna

The international organizing committee

Martha Alarcon Riquelme, Malaga (ES)
Martin Aringer, Dresden (DE)
Stefano Bombardieri, Pisa (IT)
Dimtrios Boumpas, Athens (GR)
Ricard Cervera, Barcelona (ES)
Nathalie Costedoat-Chalumeau, Paris (FR)
Mary K Crow, New York (US)
Thomas Dörner, Berlin (DE)
Keith Elkon, Seattle (US)
Paul Fortin, Quebec (CA)
Claudio Galarza-Maldonado, Cuenca (EC)
Dafna Gladman, Toronto (CA)
Caroline Gordon, Birmingham (UK)
Eva Hadaschik, Heidelberg (DE)
Bevra Hahn, Los Angeles (US)
Falk Hiepe, Berlin (DE)
Frederic Houssiau, Leuven (BE)
Gabor Illei, Gaithersburg (US)
David Isenberg, London (UK)
Soren Jacobson, Copenhagen (DK)
Joachim Kalden, Erlangen (DE)
Peter Lipsky, Charlottesville (US)
Eric Morand, Clayton (AU)
Michelle Petri, Baltimore (US)
Guillermo Pons-Estel, Barcelona (ES)
Andreas Radbruch, Berlin (DE)
Gabriela Riemekasten, Berlin (DE)
Jorge Sanchez-Guerrero, Toronto (CA)
Matthias Schneider, Düsseldorf (DE)
Vibeke Strand, Stanford (US)
George Tsokos, Boston (US)
Murray Urowitz, Toronto (CA)
Ronald Van Vollenhoven, Stockholm (SE)
Carlos Vasconcelos, Porto (PT)
Reinhard Voll, Freiburg (DE)
Daniel Wallace, Los Angeles (US)
David Wofsy, San Francisco (US)

Advisory Committee of Past Chairs

Mary Carmen Amigo, Mexico City (MX)
Shunle Chen, Shanghai (CN)
John Esdaile, Vancouver (CA)
Pao-Hsiii Feng, Singapore (SG)
Marvin Fritzler, Calgary (CA)
Graham R.V. Hughes, London (UK)
Munther A. Khamashta, London (UK)
Robert G. Lahita, New York (US)
Bernardo Pons-Estel, Rosario (AR)
Yehuda Shoenfeld, Jerusalem (IL)
Eng M. Tan, LaJolla (US)
Donato Alarcón-Segovia, Cancun (MX)
Conference Organisation
Registration and Abstract Management, Sponsoring, Corporate Satellites

LUPUS 2015 Congress Office
Vienna Medical Academy
Kristina Libova, Verena Netzer, Catherine Tomek
Alser Strasse 4, A-1090 Vienna, Austria
T: +43 1 405 13 83 -11 or -30 or -18
F: +43 1 407 82 74
E: lupus2015@medacad.org
www.medacad.org

Exhibition Management

MAW - Medizinische Ausstellungs- und Werbegesellschaft
Maria Rodler & Co GmbH
Michael Schneider, Ingrid Winkler
Freyung 6, A-1010 Vienna, Austria
T: +43 1 536 63 - 82 or -33
F: +43 1 535 60 16
E: maw@media.co.at
www.media.co.at

Hotel Accommodation

Mondial Congress & Events
Mondial GmbH & Co. KG
Ms. Daniela Lenzinger
Operngasse 20b, A-1040 Vienna, Austria
T: +43 1 58804-110
F: +43 1 58804-185
E: lenzinger@mondial-congress.com
www.mondial-congress.com
Mezzanine (1st Floor)

- Red = Lectures
- Green = Exhibition
- Blue = Scientific Posters
- Orange = Preview Centre
- Yellow = Registration
- Pink = Cash Bar
- Purple = Cloakroom
### Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 17.00</td>
<td><strong>Session 1</strong>&lt;br&gt;History of SLE</td>
</tr>
<tr>
<td>17.00 – 18.00</td>
<td><strong>Session 2</strong>&lt;br&gt;Round Table - What is burning in SLE 2020?</td>
</tr>
<tr>
<td>18.15</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>19.30</td>
<td>Welcome Reception – Exhibition Area</td>
</tr>
</tbody>
</table>

### Wednesday, September 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 08.45</td>
<td><strong>Meet the Professor 1</strong>&lt;br&gt;Lung Involvement (Room Geheime Ratstube)</td>
</tr>
<tr>
<td>09.00 – 10.45</td>
<td><strong>Session 3</strong>&lt;br&gt;What is new?&lt;br&gt;Major non-renal SLE manifestations – pathogenesis, diagnosis and therapy</td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15 – 12.50</td>
<td><strong>Session 6</strong>&lt;br&gt;Therapy of SLE: conventional drugs</td>
</tr>
<tr>
<td>13.15 – 14.15</td>
<td>Industry Sponsored Symposium&lt;br&gt;See page 46</td>
</tr>
<tr>
<td>14.30 – 16.35</td>
<td><strong>Session 9</strong>&lt;br&gt;Evaluating and assessing lupus: Better tools for a better future.</td>
</tr>
<tr>
<td>16.35 – 17.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17.00 – 18.15</td>
<td><strong>Session 12</strong>&lt;br&gt;New therapies and strategies in SLE 1</td>
</tr>
<tr>
<td>19.00</td>
<td>Mayor’s Reception – City Hall Vienna</td>
</tr>
</tbody>
</table>

### Thursday, September 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45</td>
<td><strong>Meet the Professor 2</strong>&lt;br&gt;Assessing and defining disease activity in SLE (Room Künstlerzimmer)</td>
</tr>
<tr>
<td>09.00 – 10.45</td>
<td><strong>Session 4</strong>&lt;br&gt;Role of B cell products in disease</td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15 – 12.50</td>
<td><strong>Session 7</strong>&lt;br&gt;Genetics and Epigenetics</td>
</tr>
<tr>
<td>13.15 – 14.15</td>
<td>Industry Sponsored Symposium&lt;br&gt;See page 46</td>
</tr>
<tr>
<td>14.30 – 16.35</td>
<td><strong>Session 10</strong>&lt;br&gt;Connective tissue diseases: What can lupus experts learn from others?</td>
</tr>
<tr>
<td>16.35 – 17.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17.00 – 18.15</td>
<td><strong>Session 13</strong>&lt;br&gt;Regulatory T cells in SLE</td>
</tr>
<tr>
<td>19.00</td>
<td>Mayor’s Reception – City Hall Vienna</td>
</tr>
</tbody>
</table>

### Notes
- **Festaal**: Festsaal<br>**Zeremoniensaal**: Geheime Ratstube<br>**Künstlerzimmer**: Künstlerzimmer<br>**Gartensaal**: Gartensaal
Programme at a Glance

 Friday, September 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session/Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Festsaal</td>
<td>Early bird poster viewing – Poster Area</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Meet the Professor 5 B-cell Therapy (Room Geheime Ratstube)</td>
</tr>
<tr>
<td>08.00</td>
<td></td>
<td>Meet the Professor 6 Antiphospholipid syndrome (Room Künstlerzimmer)</td>
</tr>
<tr>
<td>08.45</td>
<td></td>
<td>Meet the Professor 7 Therapy of Lupus Nephritis (Room Trabantenstube)</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Meet the Professor 8 Cutaneous SLE (Room Rittersaal)</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Session 15 Focus on patient reported outcomes</td>
</tr>
<tr>
<td>10.40</td>
<td></td>
<td>Session 16 B cells as therapeutic target</td>
</tr>
<tr>
<td>10.40</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15</td>
<td></td>
<td>Session 17 Antiphospholipid Syndrome (APS)</td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Session 18 Lessons from animal models</td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Industry Sponsored Symposium See page 47</td>
</tr>
<tr>
<td>14.15</td>
<td></td>
<td>Poster viewing with presenters – Poster Area</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td>Session 19 Pregnancy and more</td>
</tr>
<tr>
<td>16.45</td>
<td></td>
<td>Session 20 Cytokines and interferons. The role of the innate immune response in SLE</td>
</tr>
<tr>
<td>16.45</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17.15</td>
<td></td>
<td>Session 22 Early and late complications of SLE and SLE therapy / Co-morbidities</td>
</tr>
<tr>
<td>17.15</td>
<td></td>
<td>Session 23 T cells, monocytes, DC and apoptosis</td>
</tr>
<tr>
<td>18.15</td>
<td></td>
<td>Session 28 New therapies and strategies in SLE 2</td>
</tr>
<tr>
<td>18.15</td>
<td></td>
<td>Session 29 Future in basic research</td>
</tr>
<tr>
<td>18.15</td>
<td></td>
<td>Farewell Party with Sausage &amp; Beer</td>
</tr>
</tbody>
</table>

 Saturday, September 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session/Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Festsaal</td>
<td>Early bird poster viewing – Poster Area</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Session 24 Current state in lupus nephritis</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Session 25 Fc-gamma receptors and complement</td>
</tr>
<tr>
<td>10.40</td>
<td></td>
<td>Patients’ meeting From kitchen table to Capitol Hill</td>
</tr>
<tr>
<td>10.40</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15</td>
<td></td>
<td>Session 26 Guidelines and recommendations</td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Session 27 Autoantibodies</td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Industry Sponsored Symposium See page 48</td>
</tr>
<tr>
<td>14.15</td>
<td></td>
<td>Poster viewing with presenters – Poster Area</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td>Session 28 New therapies and strategies in SLE 2</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td>Session 29 Future in basic research</td>
</tr>
<tr>
<td>16.45</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td>Session 30 Summing up – a look into the future</td>
</tr>
<tr>
<td>18.15</td>
<td></td>
<td>Farewell Party with Sausage &amp; Beer</td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td>Festsaal</td>
<td><strong>Session 1 - History of SLE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: John Esdaile &amp; Josef Smolen</td>
</tr>
<tr>
<td>16.00 – 16.20</td>
<td></td>
<td><strong>OI1.1</strong> A History of SLE - New Insights into possible etiopathogenesis pathways</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eng Tan, <em>La Jolla, United States</em></td>
</tr>
<tr>
<td>16.20 – 16.40</td>
<td></td>
<td><strong>OI1.2</strong> The history of DNA antibodies and their relation to the pathogenesis of SLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joachim Kalden, <em>Erlangen, Germany</em></td>
</tr>
<tr>
<td>16.40 – 17.00</td>
<td></td>
<td><strong>OI1.3</strong> What did it take to make antibodies a multi-billion dollar success?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fritz Melchers, <em>Berlin, Germany</em></td>
</tr>
<tr>
<td>17.00 – 18.00</td>
<td>Festsaal</td>
<td><strong>Session 2 – Round Table: What is burning in SLE 2020?</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bevra Hahn, Eric Morand, Bernardo Pons-Estel, Mary Crow</td>
</tr>
<tr>
<td>18.15 – 19.30</td>
<td>Festsaal</td>
<td><strong>Opening Ceremony</strong></td>
</tr>
<tr>
<td>19.30</td>
<td>Exhibition Area</td>
<td><strong>Welcome Reception</strong></td>
</tr>
</tbody>
</table>

**Abbreviations**
- OI = Oral Presentation – Invited Talk
- OS = Oral Presentation – Submitted Abstract
- P = Poster Presentation
08.00 – 08.45
A separate registration is required to attend the „Meet the professor“ sessions (Fee: EUR 30,-)

Geheime Ratstube  Meet the Professor 1 – Lung Involvement
Marta Mosca, Pisa, Italy

Künstlerzimmer  Meet the Professor 2 – Assessing and defining disease activity in SLE
Eric Morand, Clayton, Australia

Trabantenstube  Meet the Professor 3 – Haematological SLE
David Isenberg, London, United Kingdom

Rittersaal  Meet the Professor 4 – Myositis
Frederic Miller, Bethesda, MD, United States

09.00 – 09.25
Festsaal
Session 3 - What is new?
Major non-renal SLE manifestations pathogenesis, diagnosis and therapy
Chair: Georg Stingl & David Isenberg

09.00 – 09.25  OI3.1  Haematologic manifestations
David Isenberg, London, United Kingdom

09.25 – 09.50  OI3.2  Skin involvement
Eva Hadaschik, Heidelberg, Germany

09.50 – 10.15  OI3.3  Central and peripheral neurdlupus
Tom Huizinga, Leiden, Netherlands

10.15 – 10.45  OI3.4  Lung involvement
Marta Mosca, Pisa, Italy

Zeremoniensaal  Session 4 - Role of B cell products and B cell function
Chair: Fitz Melchers & Peter Lipsky

09.00 – 09.25  OI4.1  B cell products and their clinical relevance as biomarkers
Betty Diamond, Manhasset, NY, United States

09.25 – 09.50  OI4.2  B cells and plasma cells
Reinhard Voll, Freiburg, Germany

09.50 – 10.15  OI4.3  BAFF and other B cell cytokines
Carlo Chizzolini, Geneva, Switzerland

10.15 – 10.30  OI4.4  Epratuzumab, a monoclonal antibody targeting CD22, inhibits
BCR/CD40-stimulated B cell proliferation in vitro
Anthony Shock, Slough, United Kingdom

10.30 – 10.45  OI4.5  Pharmacodynamic changes in gene expression observed in two
phase 3 trials of BAFF blockade with tabalumab in SLE
Robert Hoffman, Indianapolis, United States
09.00 – 10.45
Gartensaal

Session 5 - Oral presentations from submitted abstracts 1: Clinical science
Chair: Daniel Wallace & Kurt Derfler

09.00 – 09.15
OS5.1 Remission in SLE: consensus findings from a large international panel on definitions of remission in SLE (DORIS)
Ronald van Vollenhoven, Stockholm, Sweden

09.15 – 09.30
OS5.2 Cardiovascular Events Prior to or Early After Diagnosis of SLE
Murray Urowitz, Toronto, Canada

09.30 – 09.45
OS5.3 Use of antibiotics and subsequent risk of Systemic Lupus Erythematosus: A matched case-control study
Neda Amiri, Vancouver, Canada

09.45 – 10.00
OS5.4 Utility of untimed single urine protein/creatinine ratio as a substitute for the 24 hour proteinuria for the assessment of proteinuria in systemic lupus erythematosus
Zahi Touma, Toronto, Canada

10.00 – 10.15
OS5.5 Comparison of disease characteristics and organ damage in patients with juvenile and adult-onset systemic lupus erythematosus in large cohort from Turkey
Bahar Artim-Esen, Istanbul, Turkey

10.15 – 10.30
OS5.6 Clinical and serological differences between juvenile-onset and adult-onset systemic lupus erythematosus patients from a national registry of patients (RELESSER)
Vicenç Torrente-Segarra, Hospitalet Llobregat, Spain

10.30 – 10.45
OS5.7 Coronary-Artery Atherosclerosis in SLE patients younger than sixty years
Juanita Romero-Diaz, Mexico City, Mexico

10.45 – 11.15
COFFEE BREAK

11.15 – 12.55
Festsaal

Session 6 - Therapy of SLE: conventional drugs
Chair: Mary C. Amigo & Hans Bijlsma

11.15 – 11.40
OI6.1 Azathioprin vs Mycophenolat Mofetil
Mary Ann Dooley, Chapel Hill, NC, United States

11.40 – 12.05
OI6.2 Hydroxychloroquine and adherence to therapy
Nathalie Costedoat-Chalumeau, Paris, France

12.05 – 12.30
OI6.3 Glucocorticoids and their adverse effects: “high, low or no”
Hans Bijlsma, Utrecht, Netherlands

12.30 – 12.55
OI6.4 Can we prevent steroid-induced osteoporosis
Murray Urowitz, Toronto, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.15 – 12.55 | Zeremoniensaal | **Session 7 - Genetics and Epigenetics**  
Chair: Marta Alarcon-Riquelme & Yehuda Shoenfeld                        |
| 11.15 – 11.40 |            | OI7.1 Application of genetic signature to clinical care                  |
|             |            | Virginia Pascual, *Dallas, TX, United States*                              |
| 11.40 – 12.05 |            | OI7.2 From gene discovery to disease mechanisms                           |
|             |            | Marta Alarcon-Riquelme, *Oklahoma City, OK, United States*                 |
| 12.05 – 12.30 |            | OI7.3 Is the association of ethnicity with SLE solely genetic?             |
|             |            | John B. Harley, *Cincinnati, OH, United States*                            |
| 12.30 – 12.55 |            | OS7.4 A genetic variation in HLA-DR region associated with hypomethylation and high expression of HLA-DRB1 and DRB5 genes contribute to enhanced autoantibody production in systemic lupus erythematosus |
|             |            | Quan-Zhen Li, *Dallas, United States*                                      |
|             | Gartensaal | **Session 8 - Oral presentations from submitted abstracts 2: Basic science**  
Chair: Eva Hadaschik & Carlos Vasconcelos                                  |
<p>| 11.15 – 11.30 |            | OS8.1 The oxidative burst mediates anti-inflammatory clearance of dead cells in a mouse model of Systemic lupus Erythematosus (SLE) and inflammatory arthritis |
|             |            | Markus Hoffmann, <em>Erlangen, Germany</em>                                      |
| 11.30 – 11.45 |            | OS8.2 Aberrant microparticle and micro-RNA profiles in the circulation of SLE patients |
|             |            | Niels Heegaard, <em>Copenhagen, Denmark</em>                                     |
| 11.45 – 12.00 |            | OS8.3 Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide in Lupus |
|             |            | Sylviane Muller, <em>Strasbourg, France</em>                                    |
| 12.00 – 12.15 |            | OS8.4 Interferon regulatory factor-5 promotes disease in the MRL/lpr mouse model of lupus |
|             |            | Kei Yasuda, <em>Boston, United States</em>                                      |
| 12.15 – 12.30 |            | OS8.5 Detection of auto-antibodies directed to doublestranded DNA in SLE: comparison of different assays during quiescent and active disease |
|             |            | Karina de Leeuw, <em>Groningen, Netherlands</em>                                |
| 12.30 – 12.55 |            | OS8.6 TWEAK Receptor-Fc Suppresses Germinal Center Formation and Pathogenic B Cells in a Lupus Mouse Model via Inhibition of the TWEAK/Fn14 Pathway |
|             |            | H.K. Min, <em>Seoul, Republic of Korea</em>                                     |
| 13.15 – 14.15 | Festsaal   | <strong>Industry-Sponsored Symposium</strong> (see page 46)                           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.30 – 16.35 | Festsaal     | **Session 9 - Evaluating and assessing lupus: Better tools for a better future**  
Chair: Zhan-Guo Li & Claudio Galarza-Maldonado  

14.30 – 14.55 | OI9.1 | SLE: Diagnosis and classification  
Martin Aringer, Dresden, Germany

14.55 – 15.20 | OI9.2 | Outcome measures and trial design: pitfalls and potentials – What is the value of SRI?  
Maria Dall’Era, San Francisco, CA, United States

15.20 – 15.45 | OI9.3 | A critical assessment of current instruments for activity and damage: Assets and limitation  
Dafna Gladman, Toronto, Canada

15.45 – 16.10 | OI9.4 | Assessing and defining low disease activity in SLE  
Eric Morand, Clayton, Australia

16.10 – 16.35 |        | Round Table: Activity scores and outcome measures in the future  
Martin Aringer, Maria Dall’Era, Dafna Gladman, Eric Morand

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.30 – 16.35 | Zeremoniensaal | **Session 10 - Connective tissue diseases: What can lupus experts learn from others?**  
Chair: Ferdinand Breedveld & Christof Zimmermann

14.30 – 14.55 | OI10.1 | Endothelin - receptor antagonists in pulmonary hypertension and Raynaud's syndrome - should we use it in SLE?  
Irene Lang, Vienna, Austria

14.55 – 15.20 | OI10.2 | Primary myositis and SLE-related myositis – similarities and differences  
Fred Miller, Bethesda, MD, United States

15.20 – 15.45 | OI10.3 | Primary and secondary Sjögren’s Syndrome: similarities and differences; what are the therapeutic prospects?  
Athanasiost Zsioufas, Athens, Greece

15.45 – 16.10 | OI10.4 | Dissection of the Immunopathogenesis of celiac disease  
Frits Koning, Leiden, Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.30 – 15.30 | Künstlerzimmer | **Session 11 - Seminar: Immunology for MDs**  
Chair: Richard Di Paolo  
*A separate registration is required to attend the seminar (Fee: EUR 30,-)*

14.30 – 15.30 | OI11.1 | T cells, B cells, innate immunity and their Interactions  
Richard DiPaolo, Saint Louis, MO, United States

15.30 – 16.35 | OI11.2 | Regulatory T cells: Impact on SLE pathogenesis and auto-antibodies  
Richard DiPaolo, Saint Louis, MO, United States

16.35 – 17.00 |        | COFFEE BREAK
**Session 12 - New therapies and strategies in SLE 1**
Chair: Winfried Graninger & Dafna Gladman

17.00 – 17.25  
**OI12.1** Extracorporeal therapies in SLE  
Kurt Derfler, Vienna, Austria

17.25 – 17.50  
**OI12.2** Treat to target in SLE and therapeutic approaches  
Ronald Van Vollenhoven, Stockholm, Sweden

17.50 – 18.15  
**OI12.3** Stem cell therapy in SLE  
Dominique Farge-Bancel, Paris, France

**Session 13 - Regulatory T cells in SLE**
Chair: Ethan Shevach & Clemens Scheinecker

17.00 – 17.25  
**OI13.1** Adaptation of proinflammatory Th lymphocytes to chronic inflammation  
Andreas Radbruch, Berlin, Germany

17.25 – 17.50  
**OI13.2** Restoring regulation: IL-2 therapy in SLE  
David Klatzmann, Paris, France

17.50 – 18.15  
**OI13.3** Regulatory T cells in human diseases  
Kazuhiko Yamamoto, Tokyo, Japan

**Session 14 - Pediatric lupus**
Chair: Alberto Martini & Hermine Brunner

17.00 – 17.25  
**OI14.1** Treatment of juvenile lupus nephritis  
Alberto Martini, Genova, Italy

17.25 – 17.50  
**OI14.2** Organ involvement other than lupus nephritis in pediatric Lupus  
Hermine Brunner, Cincinnati, OH, United States

17.50 – 18.15  
**OI14.3** Outcome measures in juvenile systemic lupus erythematosus  
Nicola Ruperto, Genova, Italy

19.00  
Vienna City Hall  
**Mayor's Reception**
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 09.00</td>
<td>Poster Area</td>
<td><strong>Early Bird Poster Viewing</strong></td>
</tr>
<tr>
<td>08.00 – 08.45</td>
<td></td>
<td><strong>A separate registration is required to attend the „Meet the professor“ sessions (Fee: EUR 30,-)</strong></td>
</tr>
<tr>
<td></td>
<td>Geheime Ratstube</td>
<td><strong>Meet the Professor 5 – B-Cell Therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Thomas Dörner,</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Künstlerzimmer</td>
<td><strong>Meet the Professor 6 – Antiphospholipid syndrome</strong></td>
</tr>
<tr>
<td></td>
<td>Munther Khamashta,</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trabantenstube</td>
<td><strong>Meet the Professor 7 – Therapy of Lupus Nephritis</strong></td>
</tr>
<tr>
<td></td>
<td>Frederic Houssiau,</td>
<td>Louvain, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rittersaal</td>
<td><strong>Meet the Professor 8 – Cutaneous SLE</strong></td>
</tr>
<tr>
<td></td>
<td>Annnegret Kuhn,</td>
<td>Mainz, Germany</td>
</tr>
<tr>
<td>09.00 – 10.40</td>
<td>Festsaal</td>
<td><strong>Session 15 - Focus on patient reported outcomes</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Vibeke Strand &amp; Matthias Schneider</td>
<td></td>
</tr>
<tr>
<td>09.00 – 09.25</td>
<td>OI15.1</td>
<td>PRO - taking the patients' side</td>
</tr>
<tr>
<td></td>
<td>Vibeke Strand,</td>
<td>Portola Valley, CA, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td>OI15.2</td>
<td>Fatigue in SLE</td>
</tr>
<tr>
<td></td>
<td>Matthias Schneider,</td>
<td>Düsseldorf, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td>OI15.3</td>
<td>Using health information technology innovations to advance quality of care in SLE</td>
</tr>
<tr>
<td></td>
<td>Jinoos Yazdany,</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 – 10.25</td>
<td>Representing Patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kirsten Lerström</td>
<td></td>
</tr>
<tr>
<td>10.25 – 10.40</td>
<td>OS15.5</td>
<td>Hearing the Patient Voice: Clinical Trial Simulation Guides Phase III Study Design in Systemic Lupus Erythematosus (SLE)</td>
</tr>
<tr>
<td></td>
<td>Henk Nab, Gaithersburg, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeremoniensaal</td>
<td>Session 16 - B cells as therapeutic target</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Peter Lipsky &amp; Joachim Kalden</td>
<td></td>
</tr>
<tr>
<td>09.00 – 09.25</td>
<td>OI16.1</td>
<td>Targeting B-cells in experimental lupus</td>
</tr>
<tr>
<td></td>
<td>Mark Shlomchik,</td>
<td>Pittsburgh, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td>OI16.2</td>
<td>Targeting B-cells in human lupus</td>
</tr>
<tr>
<td></td>
<td>Thomas Dörner,</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td>OI16.3</td>
<td>Are B-cells the culprit?</td>
</tr>
<tr>
<td></td>
<td>Peter Lipsky,</td>
<td>Charlottesville, VA, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 – 10.40</td>
<td>OI16.4</td>
<td>Regulatory B cells in SLE</td>
</tr>
<tr>
<td></td>
<td>Claudia Mauri,</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>09.00 – 10.40</strong></td>
<td><strong>Gartensaal</strong></td>
<td><strong>Patients’ Meeting - Lupus World Engaged!</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Involvement</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chair: Anne Charlet</strong></td>
</tr>
<tr>
<td>09.00 – 09.25</td>
<td></td>
<td>Experience from Eular Task Force on Recommendations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Marchiori</td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td></td>
<td>Experience from International Study Group Initiatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K. Lerstrøm</td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td></td>
<td>Experience from IMI Ethics Committee</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Rubio</td>
</tr>
<tr>
<td>10.15 – 10.40</td>
<td></td>
<td>Training - What is key to a PRP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Marchiori</td>
</tr>
<tr>
<td><strong>10.40 – 11.15</strong></td>
<td></td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td><strong>11.15 – 12.30</strong></td>
<td><strong>Festsaal</strong></td>
<td><strong>Session 17 - Antiphospholipid Syndrome (APS)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chair: Graham Hughes &amp; Guillermo Pons-Estel</strong></td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td></td>
<td>OI17.1 Antiphospholipid syndrome: beyond thrombosis and miscarriages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munther Khamashta, London, United Kingdom</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td></td>
<td>OI17.2 Therapy of APS. Value and evidence of anticoagulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ricard Cervera, Barcelona, Spain</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td></td>
<td>OI17.3 Novel environmental factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yehuda Shoenfeld, Ramat Aviv, Israel</td>
</tr>
<tr>
<td><strong>Zeremoniensaal</strong></td>
<td></td>
<td><strong>Session 18 - Lessons from animal models</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chair: Bevra Hahn &amp; Keith Elkon</strong></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td></td>
<td>OI18.1 Animal models for SLE in basic research: pro and cons as models for the human disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bevra Hahn, Los Angeles, CA, United States</td>
</tr>
<tr>
<td>11.45 – 12.15</td>
<td></td>
<td>OI18.3 Pristane induced lupus and models for other CTD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Westley Reeves, Gainesville, FL, United States</td>
</tr>
<tr>
<td>12.15 – 12.30</td>
<td></td>
<td>P2.01 MiR155 deficient mice show reduced disease severity in pristane-induced lupus (PIL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harald Leiss, Vienna, Austria</td>
</tr>
<tr>
<td><strong>Gartensaal</strong></td>
<td></td>
<td><strong>Patients’ Meeting - Lupus World Engaged! (cont.)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>From Group to Patients</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chair: Anne Charlet</strong></td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td></td>
<td>Channels of Information</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Zúñiga</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td></td>
<td>Messages to share</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Canzona</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td></td>
<td>From patients to group - message from patient panel on treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Cornet</td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Session</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12.45 – 14.15</td>
<td>Festsaal</td>
<td><strong>Industry-Sponsored Symposium</strong> (see page 47)</td>
</tr>
<tr>
<td>14.15 – 15.15</td>
<td>Poster Area</td>
<td><strong>Poster Viewing with presenters</strong></td>
</tr>
<tr>
<td>15.30 – 16.45</td>
<td>Festsaal</td>
<td><strong>Session 19 - Pregnancy and more</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Munther Khamashta &amp; Robert G. Labita</td>
</tr>
<tr>
<td></td>
<td>OI19.1</td>
<td><strong>Autoantibodies and congenital heart block</strong></td>
</tr>
<tr>
<td>15.30 – 15.55</td>
<td></td>
<td>Yoshinari Takasaki, <em>Tokyo, Japan</em></td>
</tr>
<tr>
<td></td>
<td>OI19.2</td>
<td><strong>Pregnancy in SLE</strong></td>
</tr>
<tr>
<td>15.55 – 16.20</td>
<td></td>
<td>Rebecca Fischer-Betz, <em>Düsseldorf, Germany</em></td>
</tr>
<tr>
<td></td>
<td>OI19.3</td>
<td><strong>Getting beyond the heart break of neonatal lupus: Integrating bench and bedside</strong></td>
</tr>
<tr>
<td>16.20 – 16.45</td>
<td></td>
<td>Jill Buyon, <em>New York, NY, United States</em></td>
</tr>
<tr>
<td>Zeremoniensaal</td>
<td></td>
<td><strong>Session 20 - Cytokines and interferons - the role of the innate immune response in SLE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Mary Crow &amp; HM Moutsopoulos</td>
</tr>
<tr>
<td>15.30 – 15.55</td>
<td>OI20.1</td>
<td><strong>Cross regulation of cytosolic and endosomal nucleic acid sensors in systemic autoimmunity</strong></td>
</tr>
<tr>
<td></td>
<td>OI20.2</td>
<td>Anne Marshak Rothstein, <em>Worcester, MA, United States</em></td>
</tr>
<tr>
<td>15.55 – 16.20</td>
<td></td>
<td><strong>Immune complex mediated activation of plasmacytoid dendritic cells in SLE</strong></td>
</tr>
<tr>
<td></td>
<td>OI20.3</td>
<td>Lars Rönnblom, <em>Uppsala, Sweden</em></td>
</tr>
<tr>
<td>16.20 – 16.45</td>
<td></td>
<td><strong>The interferon signature</strong></td>
</tr>
<tr>
<td></td>
<td>OI21.1</td>
<td>Mary Crow, <em>New York, NY, United States</em></td>
</tr>
<tr>
<td>Gartensaal</td>
<td></td>
<td><strong>Session 21 - Health professionals</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Tanja Stamm</td>
</tr>
<tr>
<td>15.30 – 15.40</td>
<td>OI21.1</td>
<td><strong>From the perspective of patients to ICF Core Sets in SLE</strong></td>
</tr>
<tr>
<td></td>
<td>OI21.2</td>
<td>Tanja Stamm, <em>Vienna, Austria</em></td>
</tr>
<tr>
<td>15.40 – 16.05</td>
<td></td>
<td><strong>Issues of clinical practice of health professionals in SLE</strong></td>
</tr>
<tr>
<td></td>
<td>OI21.3</td>
<td>Greetje van Zuiden, <em>Groningen, Netherlands</em></td>
</tr>
<tr>
<td>16.05 – 16.25</td>
<td></td>
<td><strong>EULAR-HP’s activities in SLE</strong></td>
</tr>
<tr>
<td></td>
<td>OI21.4</td>
<td>Thea VlietVlieland, <em>Leiden, Netherlands</em></td>
</tr>
<tr>
<td>16.25 – 16.45</td>
<td></td>
<td><strong>Uncertainties and opportunities for patients with SLE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Malin Mattsson, <em>Lulea, Sweden</em></td>
</tr>
</tbody>
</table>
**Session 22 - Early and late complications of SLE and SLE therapy / Co-morbidities**

Chair: Helga Radner & Cristina Drenkard

17.15 – 17.40  **OI22.1**  The big dilemma: Infection or flare?
Stefan Winkler, Vienna, Austria

17.40 – 18.05  **OI22.2**  Atherosclerosis and coronary heart disease in SLE
Jane Salmon, New York, NY, United States

18.05 – 18.30  **OI22.3**  How can we prevent co-morbidities in SLE?
Michelle Petri, Baltimore, United States

18.30 – 18.55  **OI22.4**  Steroid sparing regimens in therapeutic resistance
Carlos Vasconcelos, Porto, Portugal

**Session 23 - T cells, monocytes, DC and apoptosis**

Chair: George Tsokos & Anne Davidson

17.15 – 17.40  **OI23.1**  T cell dysfunction in lupus
George Tsokos, Boston, MA, United States

17.40 – 18.05  **OI23.2**  Macrophages and dendritic cells in SLE
Anne Davidson, Manhasset, NY, United States

18.05 – 18.30  **OI23.3**  Cell death in the etiopathogenesis of SLE
Martin Herrmann, Erlangen, Germany

18.30 – 18.55  **OI23.4**  Role of toll like receptors in lupus pathogenesis
Keith Elkon, Washington, DC, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 09.00</td>
<td>Poster Area</td>
<td><strong>Early Bird Poster Viewing</strong></td>
</tr>
<tr>
<td>09.00 – 10.40</td>
<td>Festsaal</td>
<td><strong>Session 24 - Current state in lupus nephritis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Liz Lightstone &amp; Dimitrios Boumpas</td>
</tr>
<tr>
<td>09.00 – 09.25</td>
<td></td>
<td><strong>O124.1</strong> Pathogenesis of lupus nephritis and differences compared to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>other organ manifestations in SLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Johan van der Vlag, Nijmegen, Netherlands</td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td></td>
<td><strong>O124.2</strong> Re-thinking conventional treatment for lupus nephritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Wofsy, San Francisco, United States</td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td></td>
<td><strong>O124.3</strong> Diagnosis and therapy; to Bx or not to Bx and to Cx or not</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to Cx? AND GC-free remission</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liz Lightstone, London, United Kingdom</td>
</tr>
<tr>
<td>10.15 – 10.40</td>
<td></td>
<td><strong>O124.4</strong> Why do trials in lupus nephritis fail?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frederic Houssiau, Louvain, Belgium</td>
</tr>
<tr>
<td>Zeremoniensaal</td>
<td></td>
<td><strong>Session 25 - Fc-gamma receptors and complement</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Eric Morand &amp; Andrea Doria</td>
</tr>
<tr>
<td>09.00 – 09.10</td>
<td></td>
<td><strong>O125.1</strong> Introduction: Targeting Fc-receptors - where do we stand and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>will it help?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Richard DiPaolo, Saint Louis, MO, United States</td>
</tr>
<tr>
<td>09.10 – 09.35</td>
<td></td>
<td><strong>O125.2</strong> Stimulating CD4+ T cells through the T cell receptor and the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fc receptors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Richard DiPaolo, Saint Louis, MO, United States</td>
</tr>
<tr>
<td>09.35 – 09.45</td>
<td></td>
<td><strong>OS25.3</strong> Modulating Plasmacytoid Dendritic Cells for the Treatment of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dania Rabah, Cambridge, United States</td>
</tr>
<tr>
<td>09.45 – 10.10</td>
<td></td>
<td><strong>O125.4</strong> Targeting complement and its receptors - where do we stand</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and will it help?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Georg Böhmig, Vienna, Austria</td>
</tr>
<tr>
<td>10.10 – 10.25</td>
<td></td>
<td><strong>O125.5</strong> European Lupus 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Andrea Doria, Padova, Italy</td>
</tr>
<tr>
<td>10.25 – 10.40</td>
<td></td>
<td><strong>O125.6</strong> International Lupus 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eric Morand, Clayton, Australia</td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Session</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>09.00 – 10.40</strong></td>
<td><strong>Gartensaal</strong></td>
<td><strong>Patients’ Meeting - Lupus Patient Leader Summit</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>From kitchen table to Capitol Hill</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chairs: Kirsi Myllys &amp; Sandra Raymond</strong></td>
</tr>
<tr>
<td>09.05 – 09.15</td>
<td></td>
<td>Landscape of lupus groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Rubio</td>
</tr>
<tr>
<td>09.15 – 09.25</td>
<td></td>
<td>Challenges, opportunities and diversity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K. Lerstrøm</td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td></td>
<td>From Grassroots to Regional movement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Kallia</td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td></td>
<td>Organizing local groups to federal political player</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Gray</td>
</tr>
<tr>
<td>10.15 – 10.40</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td><strong>10.40 – 11.15</strong></td>
<td></td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td><strong>11.15 – 12.30</strong></td>
<td><strong>Festsaal</strong></td>
<td><strong>Session 26 - Guidelines and recommendations</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Peter Heil &amp; Stefano Bombardieri</td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td></td>
<td>OI26.1 Cutaneous LE: Therapeutic Options in 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annegret Kuhn, Mainz, Germany</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td></td>
<td>OI26.2 EULAR recommendations for lupus nephritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dimitrios Boumpas, Athens, Greece</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td></td>
<td>OI26.3 An approach to prevention of SLE: Economics &amp; Diagnostic Testing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marvin Fritzler, Calgary, Canada</td>
</tr>
<tr>
<td><strong>Zeremoniensaal</strong></td>
<td></td>
<td><strong>Session 27 - Autoantibodies</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Falk Hiepe &amp; Günter Steiner</td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td></td>
<td>OI27.1 Autoantibody secreting plasma cells as therapeutic target in SLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Falk Hiepe, Berlin, Germany</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td></td>
<td>OI27.2 B cell subsets and their role in the secretion of auto- abs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yoshiya Tanaka, Kitakyushu, Japan</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td></td>
<td>OI27.3 Autoantibodies: pathogenetic or epiphenomena?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Pisetsky, Durham, NC, United States</td>
</tr>
<tr>
<td><strong>Gartensaal</strong></td>
<td></td>
<td><strong>Patients’ Meeting - Lupus Patient Leader Summit</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Join the Conversation! Uniting the world lupus groups. Workshop (R. Rickenbach)</td>
</tr>
<tr>
<td><strong>12.45 – 14.00</strong></td>
<td><strong>Festsaal</strong></td>
<td><strong>Industry-Sponsored Symposium (see page 48)</strong></td>
</tr>
<tr>
<td><strong>14.15 – 15.15</strong></td>
<td><strong>Poster Area</strong></td>
<td><strong>Poster Viewing and tours with presenters</strong></td>
</tr>
</tbody>
</table>
Scientific Programme | Saturday, September 5

14.00 – 16.45  Gartensaal  Patients’ Meeting - Lupus Patient Leader Summit
Aspiration and Inspirations
Chairs: Katharine Wheeler & Duane Peters

14.10 – 14.25  Lupus Advocacy - South America
TBC

14.25 – 14.45  Lupus in Canada
T. Carlton

14.45 – 15.05  Lupus in Europe
A. Canzona

15.05 – 15.45  Lupus in Asia - Indonesia & Philippines
E. Pratomo, A. Bisoño, M. Robles

14.45 – 15.05  Lupus Advocacy in Practice
K. Schofield

15.05 – 15.45  Lupus in Asia - Indonesia & Philippines
E. Pratomo, A. Bisoño, M. Robles

15.45 – 16.05  Lupus Advocacy in Practice
K. Schofield

16.05 – 16.20  Lupus2017 - Melbourne, Australia
TBC

16.20 – 16.45  Discussion

15.30 – 16.45  Festsaal  Session 28 - New therapies and strategies in SLE 2
Chair: Andrea Doria & Ronald van Vollenhoven

15.30 – 15.55  OI28.1  Biologicals: evidence, trials, state of the art
Daniel Wallace, Los Angeles, CA, United States

15.55 – 16.20  OI28.2  New drugs for SLE: what is in the pipeline, what will be targeted next?
Richard Furie, Manhasset, NY, United States

16.20 – 16.45  OI28.3  Jakinibs in SLE
Mariana Kaplan, Bethesda, MD, United States

15.30 – 16.45  Zeremoniensaal  Session 29 - Future in basic research
Chair: Ethan Shevach & Sören Jacobsen

15.30 – 15.55  OI29.1  Tolerisation in allergy. What can we learn for lupus?
Ulrike Baranyi, Vienna, Austria

15.55 – 16.20  OI29.2  Regulatory T cells and their potential therapeutical role in systemic autoimmune diseases
Ethan Shevach, Bethesda, MD, United States

16.20 – 16.45  OI29.3  Role of Cbl-b in autoimmunity and cancer
Josef Penninger, Vienna, Austria
17.00 – 18.15  Festsaal  
**Session 30 - Summing up - a look into the future**  
Chair: David Wofsy & Georg Stummvoll

17.00 – 17.25  
The collective Explicitome and in silico discovery for novel treatments  
Barend Mons, *Leiden, The Netherlands*

17.25 – 17.45  
**OI30.1**  
Basic science wrap up  
Mary Crow, *New York, NY, United States*

17.45 – 18.05  
**OI30.2**  
Clinical science wrap up  
Peter Schur, *Boston, MA, United States*

18.05 – 18.10  
Best Poster Awards

18.10 – 18.15  
**OI30.4**  
At the end: A new beginning  
Josef Smolen, *Vienna, Austria*

18.15  Exhibition Area  
**Farewell Party with Sausages & Beer**
Scientific Programme | Poster Presentations

Poster Topics P01 – P05 (I): will be presented on Friday, September 4, 2015 at 14:15 – 15:15 hrs

**P01 T cells and immune regulation**

P1.02
Mucosal-associated invariant T cells are numerically and functionally deficient in stemic lupus erythematous
Yong-Wook Park, Gwangju, Korea, Republic of

P1.03
Increased expression of Inducible Costimulator Ligand (ICOSL) on CD4+ T cells in patients with SLE
Minyoung Her, Busan, Korea, Republic of

P1.04
Deficient transcriptional regulation of the E3 ligase Cbl-b by early growth response genes 2 and 3 in CD4+ T cells from systemic lupus erythematous patients
Jorge Alcocer-Varela, Mexico city, Mexico

P1.05
Modulation of p27kip1 by the E3 ligase Cbl-b regulates the interplay between regulatory and effector T cells in patients with systemic lupus erythematous
Diana Gomez-Martin, Mexico city, Mexico

P1.06
New insights into the mechanism of Galectin-1-induced T-cell apoptosis regulation and its relevance to systemic lupus erythematous
László Kovács, Szeged, Hungary

P1.07
Monitoring and modulation of follicular helper T cells in lupus
Di Yu, Clayton, Australia

P1.08
Expression of costimulatory marker on CD134 and PD-1 on T follicular helper cells (Tfh)
Sebastian Dolff, Essen, Germany

P1.09
Mechanisms of Loss of tolerance in systemic lupus erythematous
Raja Rekik, Tunis, Tunisia

P1.10
Immunomodulator effect of Vitamin D in the mononuclear cells of SLE patients
Emilia Sato, Sao Paulo, Brazil

P1.11
Environmental Triggers of Lupus Flares: The Roles of Oxidative Stress and Diet
Bruce Richardson, Ann Arbor, MI, United States

P1.12
A role for interleukin-21 in the pathogenesis of systemic lupus erythematous
Ji-Min Kim, Daegu, Republic of Korea

**P02 B-cells and autoantibodies**

P2.01
MiR155 deficient mice show reduced disease severity in pristane-induced lupus (PIL)
Harald Leiss, Vienna, Austria

P2.02
Altered localization of CD19+ B cells in the splenic germinal centers of IFN-γ-receptor-1 deficient lupus-prone MRL+/+ mice
Hideharu Sekine, Fukushima, Japan

P2.03
Concordance of Increased B1 Cell Subset and Lupus Phenotypes in Mouse and Human Dependent on BLK Expression Levels
Marta Alarcon-Riquelme, Granada, Spain

P2.04
The significance of Neutrophil Extracellular traps and B lymphocytes in renal tissue of patients with lupus nephritis
Guang-qun Xing, Qingdao, China

P2.05
B cell derived IL-4 induces proteinuria and foot process effacement
Alfred Kim, Saint Louis, United States

P2.06
Sjögren's manifestations in aged mice arise from early life germinal centers
Rachel Ettinger, Gaithersburg, United States

P2.07
Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus
Fleur Schaper, Groeningen, Netherlands

P2.08
Therapeutic implications of the immunostimulatory properties of SLE immune complexes
Jaromir Vlach, Billerica, United States

P2.09
Identification of homogeneous systemic lupus erythematosus (SLE) patient groups using clustered autoantibody reactivities
Petra Budde, Dortmund, Germany

P2.10
The fluorescence ratio provides a reliable way to study BCR signaling in patients
Emil Nashi, Montreal, Canada

P2.11
B1 cell abnormalities in patients with systemic lupus erythematous
Emil Nashi, Montreal, Canada

P2.12
Antiphospholipid antibodies in lupus nephritis and their role in long-term renal outcome
Ioannis Parodis, Stockholm, Sweden

P2.13
Decreased IL-10+ regulatory B-cells (Bregs) in lupus nephritis patients
Sebastian Dolff, Essen, Germany

P2.14
IL-21 dependent Granzyme B production of B-cells is decreased in patients with systemic lupus erythematous (SLE)
Sebastian Dolff, Essen, Germany

P2.15
Pristane induced lupus and models for other CTD
Westley Reeves, Gainesville, United States
P2.16
Study of serum anti-nucleosomal antibodies as marker of renal affection in a cohort of Egyptian SLE patients.
Marwa Soliman, Alexandria, Egypt

P2.17
Evidence for the waste disposal hypothesis: CR3 polymorphism SNP1143679 is associated with enhanced class switching of nucleic acid-specific antibodies and multi-organ involvement in SLE
Jozsef Prechtl, Budapest, Hungary

P03 (Auto-)immunity (misc.)
P3.01
In vitro induced regulatory T-Cells reduce organ involvement in a murine model of Systemic Lupus Erythematosus
Irina Gessl, Wien, Austria

P3.02
Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation through miR-21-containing exosomes: a novel innate inflammatory pathway in systemic lupus erythematosus
Wael Jarjour, Columbus, United States

P3.03
Interferon regulatory factor 5 promotes disease in the FcγRIIB-/- mouse model of lupus through TLR7-dependent and -independent pathways
Hanni Menn-Josephy, Boston, United States

P3.04
Regulatory haplotypes in HLA-D modulate transcription of multiple genes in the antigen presentation pathway and potentiate systemic autoimmunity
David Karp, Dallas, United States

P3.06
Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities in Human Immune Cells
Timothy Niewold, Rochester, United States

P3.07
IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis
Amanda Watkins, Boston, United States

P3.08
Surface expression of Stabilin-2 in peripheral blood mononuclear cells in patients with systemic lupus erythematosus
Sung-Hoon Park, Daegu, Korea, Republic of

P3.10
Myxovirus resistance protein 1 (Mx1) levels are elevated in T cells of the patients with SLE and serum Mx1 is a marker of Neuropsychiatric SLE
Shinsuke Yasuda, Sapporo, Japan

P3.11
Blood-brain barrier damages in the pathogenesis of acute confusional state in systemic lupus erythematosus
Shunsei Hirohata, Kanagawa, Japan

P3.12
Association study of LILRA4 with systemic lupus erythematosus in a Japanese population
Aya Kawasaki, Tsukuba, Japan

P3.13
An Estrogen Receptor alpha functional mutant is protective in murine lupus
Melissa Cunningham, Charleston, United States

P3.14
Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function
Mo Yin Mok, Pokfulam Road, Hong Kong

P3.15
High Interferon GeneSignature is associated with increased disease activity and oral corticosteroid use in lupus
Koustubh Ranade, Gaithersburg, United States

P3.16
Utilization of a combined family-based/case-control cohort for the ImmunoChip identifies SLE loci not previously seen in standard case-control studies
Patrick Gaffney, Oklahoma City, United States

P3.17
Engagement of BAFF with its receptor and its regulation by prednisone treatment in patients with System Lupus Erythematosus
Robert Quinet, New Orleans, United States

P3.18
SLE-Key™ rule-out serologic test for SLE using the immunarray ICHIP™
Scott Batty, Richmond, United States

P3.20
Circulating hsa-miR-30e-5p, hsa-miR-92a-3p and hsa-miR-223-3p may be novel biomarkers for Systemic lupus erythematosus
Chang-Hee Suh, Suwon, Korea, Republic of

P3.21
Decreased free protein S can be biomarker of disease activity, but not associated with subclinical atherosclerosis in SLE
Chang-Hee Suh, Suwon, Korea, Republic of

P3.22
Depletion of sCD40L and VEGF is associated with thrombotic thrombocytopenic purpura (TTP) in SLE patients
Javier Merayo-Chalico, Mexico City, Mexico

P3.23
Epidermal injury promotes activation of nephritis in lupus-prone mice
J. Michelle Kahlenberg, Ann Arbor, United States

P3.24
Profile of cytokines and chemokines in peripheral blood in Colombian patients with lupus nephritis
Henry Gonzalez-Torres, Barranquilla, Colombia
P3.25
Role of pSYK in inflammatory skin diseases
Joerg Wenzel, Bonn, Germany

P3.26
Heart rate variability is associated with TNF and INF I mediated signaling in SLE
Aikaterini Thanou, Oklahoma City, United States

P3.27
Neutrophil extracellular traps from systemic lupus erythematosus patients elicit a proinflammatory response in macrophages
Ana Barrera-Vargas, Mexico City, Mexico

P3.28
Suppression of lupus development by manipulating microRNA Activity
Nan Shen, Shanghai, China

P3.29
Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus
Claudia Günther, Dresden, Germany

P3.30
Immune cells in urine as biomarkers in SLE
Stephen Clarke, Worcester, United States

P3.31
IFNλ, known to be highly expressed in cutaneous lupus erythematosus, acts on dermal fibroblasts
Adewonuola Alase, Bradford, United Kingdom

P3.32
Increased Interferon activity is associated with progression from Early Incomplete Lupus Erythematosus to SLE
Alaa Mohamed, Leeds, United Kingdom

P3.33
The levels of n-3 and n-6 polyunsaturated fatty acids in patients with systemic lupus erythematosus and their association with serological and clinical characteristics
Magdalena Szymryka-Kaczmarek, Wroclaw, Poland

P3.34
Complement C3 does not contribute to the lupus-like disease elicited by topical treatment with Imiquimod
Chiara Giacomassi, London, United Kingdom

P3.35
Autoimmune Diseases And Systemic Lupus Erythematosus: Fortuitous Association Or Continuum?
Djanette Hakem, Algiers City, Algeria

P3.36
Promoter methylation of genes in the innate immune system and microRNA 146a expression in systemic lupus erythematosus: Potential new therapeutic targets
Beverly Lyn-Cook, Jefferson, United States

P3.37
Abdominal lesions revealing a systemic disease
Djanette Hakem, Algiers City, Algeria

P3.38
Stochastic sensing determination of serum and salivary interleukin-6 in low disease activity systemic lupus erythematosus patients
Alina Dima, Bucharest, Romania

P3.39
Looks may be deceiving: autoimmunity versus clinical presentation in systemic lupus erythematosus
Alexandra Burlui, Iasi, Romania

P4.01
5-year organ damage and safety in patients with serologically-active SLE treated with belimumab plus standard care
Ronald van Vollenhoven, Stockholm, Sweden

P4.02
Assessing satisfaction with treatment options and medical care in Systemic Lupus Erythematosus (SLE): Development of the Lupus Satisfaction Questionnaire (LSQ)
Sulabha Ramachandran, Winter Park, United States

P4.03
Belimumab 24-month treatment outcomes in patients with systemic lupus erythematosus (SLE) with high disease activity: Results from the OBServe real-world study
Christopher Collins, Washington, United States

P4.04
Adherence to treatment - Patient to patient panel outcomes
Alain Cornet, Ottignies, Belgium

P4.05
Management of primary and secondary non-responders to B cell depletion therapy in systemic lupus erythematosus: Results from the first 100 patients at a single centre
Md Md Yusof, Leeds, United Kingdom

P4.06
Late-onset neutropenia following rituximab treatment in patients with systemic lupus erythematosus
Ioannis Parodis, Stockholm, Sweden

P4.07
Long-term safety of rituximab in systemic lupus erythematosus: Repeat cycles are associated with low rates of hypogammaglobulinaemia
Daniel Shaw, Leeds, United Kingdom

P4.08
PPARγ agonists in the prevention and treatment of murine systemic lupus erythematosus
Tamar Aprahamian, Boston, United States

P4.09
Aseptic necrosis of femoral head in systemic lupus erythematosus
Masaya Mukai, Sapporo, Japan

P4.10
Subcutaneous immunoglobulin in the treatment of systemic lupus erythematosus - a case report
Ana Brasileiro, Lisboa, Portugal

P4.11
Hydroxychloroquine Blood Levels in SLE: Clarifying dosing controversies and improving adherence
Laura Durcan, Baltimore, United States

P4.12
RING, an investigator-initiated trial aimed at testing the efficacy of rituximab in refractory lupus nephritis: rationale, trial design and call for participation
Frédéric Houssiau, Bruxelles, Belgium

P4.13
H.P. Acthar gel (Acthar) attenuates disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) requiring corticosteroids
Richard Furie, Hempstead, United States
P4.14 Evaluation Of Use of Belimumab in Clinical Practice Settings (OBServe) in Argentina Mercedes Garcia, La Plata, Argentina

P4.15 Long term efficacy and safety of tacrolimus as a maintenance therapy for lupus nephritis WNA-HEE YOO, JEONJU, Korea, Republic of

P4.16 Targeted plasmacytoid dendritic cell (pDC) depletion with an anti-CD123 mAb - a potential novel treatment for Systemic Lupus Erythematosus (SLE) Shereen Oon, Parkville, Australia

P4.17 Multi-state modelling predictions of organ damage in SLE patients treated with belimumab plus standard of care James Fettiplace, Uxbridge, United Kingdom

P4.18 Treatment with anti-HMGB1 monoclonal antibody does not alleviate lupus nephritis in MRL/lpr mice Fleur Schaper, Groeningen, Netherlands

P4.19 Long-term preserved renal function in class III or IV lupus nephritis without aggressive immunosuppression Emilie Rijnink, Leiden, Netherlands

P4.20 A single-site, investigator-initiated, open-label trial of the adrenocorticotropic hormone analog H.P. Acthar® Gel (repository corticotropin injection) among subjects with active systemic lupus erythematosus Justus Fiechtner, Lansing, United States

P4.21 Hydroxychloroquine use in lupus patients during pregnancy is associated with prolonged pregnancy duration in preterm births by over one week S Kroese, Utrecht, Netherlands

P4.22 Systemic Lupus Erythematosus and Progressive Multifocal Leukoencephalopathy: focus on lymphopenia Filipa Lourenço, Lisboa, Portugal

P4.23 Lymphocyte depletion, recovery and efficacy in NZBWF1 lupus mice following continuous or intermittent dosing regimen of Venetoclax (ABT-199), a potent and selective BCL-2 Inhibitor Li Chun Wang, Worcester, United States

P4.24 Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan in vitro Li Chun Wang, Worcester, United States

P4.25 Plasma soluble Vascular Adhesion Molecule-1 (sVCAM-1) as an exploratory marker of response to therapy in patients with persistently active Systemic Lupus Erythematosus (SLE) Dima Decker, Ellicott City, United States

P4.26 Ultrasoluble curcumin/turmeric significantly reduces lymphadenopathy and proteinuria in MRL-lpr/lpr mice, but only curcumin increases survival R. Scofield, Oklahoma City, United States

P4.27 Variations of BOLD: Can hydroxychloroquine be temporarily stopped during clinical trials in SLE? Joan Merrill, Oklahoma City, United States

P4.28 Short term effect of Belimumab on endothelial progenitor cells in patients with Systemic Lupus Erythematosus Francesca Romana Spinelli, Roma, Italy

P4.29 Decreased disease activity and corticosteroid usage and improved quality of life during belimumab treatment in patients with systemic lupus erythematosus - a prospective real-life observational study Ioannis Parodis, Stockholm, Sweden

P4.30 IFNa kinoid induces neutralizing anti-IFNa antibodies that decrease the expression of IFN-induced and B cell activation associated transcripts : analysis of extended follow-up data from the IFN-K phase I/II study Julie Ducreux, Brussels, Belgium

P4.31 Effect of mofetil mycophenolate induction therapy in renal survival in patients with proliferative lupus nephritis Renzo Valdivia-Vega, Lima, Peru

P4.32 CCL20 as a biomarker of disease activity and cardiovascular risk in SLE Eoghan McCarthy, Manchester, United Kingdom

P4.33 Belimumab treatment in the real life: report on a small series of patients with systemic lupus erythematosus Gian Domenico Sebastiani, Roma, Italy

P4.34 Belimumab in systemic lupus erythematosus after inadequate response to a cocktail of active therapies Panagiotis Athanassiou, Thessaloniki, Greece

P4.35 Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice Miranda Vieson, Blacksburg, United States

P4.36 Human embryonic stem cell-derived hemangio-mesenchymal cells (HMCs) prevent lupus nephritis progression and extend lifespan in lupus-prone NZB x NZW F1 mice Erin Kimbrel, Marlborough, United States

P4.37 Clinically Meaningful Change Estimates for Generic Patient Reported Tools Used in SLE against various disease activity endpoints Meenakshi Jolly, Chicago, IL, United States
P05 Epidemiology and clinical research - I
P5.01 Analysis of cardiovascular events (CVE) in a large nationwide cohort of patients with systemic lupus erythematosus: RELESSER Registry
Sara Manrique-Arija, Málaga, Spain
P5.02 Immunosuppressant treatment patterns in lupus nephritis: a retrospective US claims database analysis
Shih-Yin Chen, Cambridge, United States
P5.03 Influence of clinical and immunological activity in pregnancies of women with systemic lupus erythematosus
Eduardo Ucar, BILBAO, Spain
P5.04 Analysis of cerebrospinal fluid anti-NR1 glutamate receptor antibodies in neuropsychiatric systemic lupus erythematosus
Eisuke Ogawa, Sagamihara, Japan
P5.05 Damage and mortality in Systemic Lupus Erythematosus: Cluster analysis of patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)
JM Pego-Reigosa, Vigo, Spain
P5.06 Increased Low Density Lipoprotein Particle Numbers in High Versus Low SLE Activity, A Potential Mechanism for Enhanced Cardiovascular Risk
Laura Durcan, Baltimore, United States
P5.07 Symptoms of attention deficit hyperactivity disorder in patients with systemic lupus erythematosus
Mo Yin Mok, Pokfulam Road, Hong Kong
P5.08 Systemic lupus erythematosus patients with past neuropsychiatric involvement is associated with cognitive impairment: a longitudinal study
Mo Yin Mok, Pokfulam Road, Hong Kong
P5.09 Quality of life in SLE of various disease durations and in correlation to disease burden. A cross sectional study
Elias Jönsson, Östersund, Sweden
P5.10 The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
Munther Khamashta, London, United Kingdom
P5.11 Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe SLE
Richard Furie, New York, United States
P5.12 Hydroxychloroquine level variability and predictors in patients with connective tissue diseases
Sarfaraz Hasni, Bethesda, United States
P5.13 PRECISESADS: Towards a Reclassification of the Systemic Autoimmune Diseases Through a -OMICS Approach
Marta Alarcon-Riquelme, Granada, Spain
P5.14 Cardiovascular disorders in a multi-ethnic cohort of patients with Systemic Lupus Erythematosus from Berkshire, United Kingdom
Simona Gindea, Slough, United Kingdom
P5.15 Peripheral nervous system involvement in SLE evaluated in a single centre over a fourteen-year study period
Alessandra Bortoluzzi, Cona (Ferrara), Italy
P5.16 Damage accrual in a group of systemic lupus erythematosus (SLE) patients deceased during a 10-year period
Ivan Padjen, Zagreb, Croatia
P5.17 Circulating levels of iC3b and C3 levels correlate with SLEDAI-2K Responder Index-50 (S2K RI-50) disease activity scores, the CASTLE (Complement Activation Signatures in Systemic Lupus Erythematosus (SLE)) study
Alfred Kim, Saint Louis, United States
P5.18 Cumulative incidence, associated factors and clinical impact of severe infections in a cohort of over 3,500 patients with Systemic Lupus Erythematosus
Iñigo Rua-Figueroa, Las Palmas GC, Spain
P5.19 Is Age of Lupus Onset a Predictor of Renal Disease Severity?
Diane Kamen, Charleston, United States
P5.20 An Australian story: patient perceptions of SLE flare activity, symptoms, triggers and management.
Marline Squance, New Lambton Heights NSW 2305, Australia
P5.21 Cognitive and emotional processing in systemic lupus erythematosus: An fMRI study
Ben Parker, Manchester, United Kingdom
P5.22 Elevated Level of Plasma Coagulation Factor XIII Correlates To Atherosclerosis In Lupus Patients
Isao Matsuura, Los Angeles, United States
P5.23 RAPID3 and Physician Global Correlate Well with SELENA-SLEDAI in Systemic Lupus Erythematosus Patients
S. Sam Lim, Atlanta, United States
P5.24 Population-based analysis of hospitalizations in Sardinia, a West-European region, reveals major changes in hospital utilization for patients with Systemic Lupus Erythematosus over the period 2001-2012
Matteo Piga, Monserrato, Italy
P5.25 Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: factors associated with accrual of damage and central nervous system involvement
Matteo Piga, Monserrato, Italy
30

P5.26
Association between atherosclerosis and cardiovascular disease in SLE patients
Susan Kay, Odense, Denmark

P5.27
Effect of supervised physical exercise in adipokines in patients with systemic lupus erythematosus
Emilia Sato, Sao Paulo, Brazil

P5.28
A signal of improvement in lupus disease activity at 3 months predicts further valid improvement at 6 months
Zahi Touma, Toronto, Canada

P5.29
Incidence and factors associated with the presence of cardiac alterations in patients with systemic lupus erythematosus - data from a Inception cohort
Carlos Castrejon Morales, Mexico, Mexico

P5.30
Vitamin D and bone mineral densities in female patients with systemic lupus erythematosus
Klara Amdahl, Stockholm, Sweden

P5.31
Plasma myeloperoxidase levels are inversely associated with future piHDL formation in women with SLE
Maureen McMahon, Los Angeles, United States

P5.32
Risk factors for osteoporosis and fragility fractures in pre-menopausal women with Systemic Lupus Erythematosus
Linda Carli, Siena, Italy

P5.33
Plasma cytokines and chemokines profile in patients with Systemic Lupus Erythematosus: its potential use as biomarkers of kidney damage
Gustavo Aroca Martinez, Barranquilla, Colombia

P5.34
Prognosis, Survival and Renal Function in Patients with Lupus Nephritis
Gustavo Aroca, Barranquilla, Colombia

P5.35
Joint involvement in patients affected by Systemic Lupus erythematosus: application of the Swollen to Tender joint count Ratio
Fulvia Ceccarelli, Roma, Italy

P5.36
Long-term outcomes and predictors of mortality in systemic lupus erythematosus (SLE) associated pulmonary arterial hypertension (PAH)
Mengtao Li, Beijing, China

P5.37
Influence of Socioeconomic Factors on Phenotype and Disease Activity Degree in Chinese Patients with Systemic Lupus Erythematosus
Mengtao Li, Beijing, China

P5.38
Lymphopenia through out Systemic Lupus Erythematosus (SLE) evolution: impact on activity, organ system involvement and damage
Raquel Faria, Porto, Portugal

P5.39
Anemia through out Systemic Lupus Erythematosus evolution: impact on activity, organ system involvement and damage
Raquel Faria, Porto, Portugal

P5.40
Breastfeeding Practice in Patients with Systemic Lupus Erythematosus
Maria Noviani, Durham, United States

P5.41
Depression as a risk factor for severe damage in systemic lupus erythematosus patients
Tatiana Lisitsyna, Moscow, Russian Federation

P5.42
Lupus cystitis in Korean patients with systemic lupus erythematosus: risk factors and clinical outcomes
Seung-Ki Kwok, Seoul, Korea, Republic of

P5.43
Systemic Lupus Erythematosus in Spanish males (RELESSER)
Anne Riveros Frutos, Barcelona, Spain

P5.44
Pregnancy and Patients with Preexisting Lupus Nephritis: 15 Years of Experience at a Single Center in Korea
Jung Hee Koh, Seoul, Korea, Republic of

P5.45
New approach to diagnosing pulmonary vasculitis in systemic lupus erythematosus
Iana Leineman, Saint Petersburg, Russian Federation

P5.47
Measurement of health status with the Patient Reported Outcomes Measurement Information System (PROMIS) instruments in adults with systemic lupus erythematosus
Rosalind Ramsey-Goldman, Chicago, United States

P5.48
B cell activating factor (BAFF) in serum and systemic lupus erythematosus disease activity using SLEDAI-2K scoring system (East Bohemian regional study)
Zbynek Hrnčíř, Hradec Králové, Czech Republic

P5.49
Impact of free light-chain immunoglobulins in serum as biomarkers of disease activity in systemic lupus erythematosus
Zbynek Hrnčíř, Hradec Králové, Czech Republic

P5.50
Application of the 2012 Systemic Lupus International collaborating clinics classification criteria on a multicenter group of Turkish systemic lupus erythematosus patients
Sule Yavuz, ISTANBUL, Turkey

P5.51
Arterial wall stiffness in systemic lupus erythematosus
Kerstin Jensen-Urstad, Stockholm, Sweden
P5.52
Systemic Lupus Erythematosus (SLE) diagnosed during hospitalization: greater disease activity, damage and short-term death
Romina Hassan, Ciudad Autonoma de Buenos Aires, Argentina

P5.53
Neurological disorders in Systemic lupus erythematosus
Maria Castellanos, Guatemala, Central America, Guatemala

P5.54
Risk factors for the development of chronic kidney disease in lupus nephritis: assessment of a retrospective cohort from a single tertiary center in southern Brazil
Odilrei Monticielo, Porto Alegre, Brazil

P5.55
Anti-N-methyl-D-aspartate receptor antibody is associated with fibromyalgia in patients with systemic lupus erythematosus
Shin-Seok Lee, Gwangju, Korea, Republic of

P5.56
Cognitive Symptoms Inventory performance as a tool to trace neurocognitive deficit symptoms in patients with systemic lupus erythematosus
Marina Micelli, Buenos Aires, Argentina

P5.57
Cognitive deficit in systemic lupus erythematosus: frequency and general features.
Marina Micelli, Buenos Aires, Argentina

P5.58
Diet and glucocorticoid treatment in patients with SLE
Cecilia Lourdudoss, Stockholm, Sweden

P5.59
Comparison of clinical and serological manifestations among juvenile-, adult-, and late-onset systemic lupus erythematosus patients in Korea
Shin-Seok Lee, Gwangju, Korea, Republic of

P5.60
Systemic Lupus Erythematosus Complicated by Neuromyelitis Optica
Amel Rezgui, Sousse, Tunisia

P5.61
Pulmonary arterial hypertension and interstitial lung disease in SLE
Chang-Hee Suh, Suwon, Korea, Republic of

P5.62
The Relationship between Organ Damage and Quality of Life in Portuguese Patients with Systemic Lupus Erythematosus
Filipa Lourenço, Lisboa, Portugal

P5.63
The association with Vitamin D levels and disease activation in systemic lupus erythematosus
Chang Keun Lee, Seoul, Korea, Republic of

P5.64
Comparison of Health-Related Quality of Life in Chilean Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis and Systemic Sclerosis
Mirentxu Iruretagoyena, Santiago, Chile

P5.65
Dietary micronutrient intake and atherosclerosis in SLE patients
Cecilia Lourdudoss, Stockholm, Sweden

P5.66
Lupus and pregnancy: A challenge!
Djanette Hakem, Algiers City, Algeria

P5.67
Could be young age at Systemic Lupus Erythematosus diagnosis a predictive factor for neuropsychiatric involvement?
Ioana Saulescu, Bucharest, Romania

P5.68
What other autoimmune diseases can be associated with Systemic Lupus Erythematosus
Neirouz Ghannouchi, Sousse, Tunisia

P5.69
Rhupus. The coexistence of systemic lupus erythematosus and rheumatoid arthritis
Panagiots Athanassiou, Thessaloniki, Greece

P5.70
Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus
Helena Tydén, Lund, Sweden

P5.71
Awareness of pregnancy issues and patient’s options in a cohort of fertile lupus patients
Daniela Opris, Bucharest, Romania

P5.72
Neuropsychiatric Manifestations in systemic Lupus Erythematosus
Ghannouchi Neirouz, Sousse, Tunisia

P5.73
Immune cytopenias in systemic lupus erythematosus
Ghannouchi Neirouz, Sousse, Tunisia

P5.74
Cardiac manifestations of systemic lupus erythematosus
Ghannouchi Neirouz, Sousse, Tunisia

P5.75
Trends of lupus nephritis in Lebanon
Imad Uthman, Beirut, Lebanon

P5.76
Cerebral Vasculitis in Lupus
Amel Rezgui, Sousse, Tunisia

P5.77
Evaluation of cognitive function by electrophysiological study in systemic lupus erythematosus patients with previous neuropsychiatric involvement
Mo Yin Mok, Pokfulam Road, Hong Kong

P5.78
Gender differences in Systemic Lupus Erythematosus patients - experience of a Portuguese Rheumatology Center
Ana Águeda, Aveiro, Portugal

P5.79
The Risk of Mortality in Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Sharan Rai, Richmond, Canada

P5.80
Admissions during 2014 year in patients with systemic lupus erythematosus in a tertiary university hospital in southern Brazil
Odilrei Monticielo, Porto Alegre, Brazil
P5.81 Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil
Odilei Monticielo, Porto Alegre, Brazil

P5.82 Preliminary studies of the LFA Rapid Evaluation of Activity in Lupus (REAL) to improve consistency and interpretability of SLE patient progress in clinical trials and real world clinics
Anca Askanase, New York, United States

P5.83 A Tunisian experience in Neuropsychiatric Lupus Erythematosus
Amel Rezgui, Sousse, Tunisia

P5.84 Serum Anti-Müllerian Hormone levels in SLE patients and healthy controls
Gerardo Marino, Rome, Italy

P5.85 Biomarkers in lupus nephritis: the possible role of serum Cystatin C, serum β2-microglobulin, urinary α1-microglobulin and ACR
Elisa Gremese, Rome, Italy

P5.86 Interstitial inflammatory infiltrate at renal biopsy and outcomes of class IV lupus nephritis
Valentina Varriano, Rome, Italy

P5.87 The triple X chromosome mosaic, 45,X/46,XX/47,XXX, among women with systemic lupus erythematosus
Hal Scaife, Oklahoma City, United States

P5.88 Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Determine Diagnosis of Systemic Lupus Erythematosus in Subacute Cutaneous Lupus Erythematosus
Victoria Werth, Philadelphia, United States

P5.89 Longitudinal, incremental direct medical costs of lupus nephritis amongst a general population-based cohort of systemic lupus erythematosus
Natalie McCormick, Vancouver, Canada

P5.90 Early Lupus Project - One-year follow-up of an Italian cohort of patients with Systemic Lupus Erythematosus of recent onset
Gian Domenico Sebastiani, Roma, Italy

P5.91 Antinuclear antibodies are associated with all-cause mortality and cardiovascular outcomes in the general population
David Karp, Dallas, United States

P5.92 Longitudinal, incremental direct medical costs of systemic lupus erythematosus for the first five years after diagnosis: a general population-based cohort study
Natalie McCormick, Vancouver, Canada

P5.93 Factors Predictive of Flares in Systemic Lupus Erythematosus Patients: Data from a Multiethnic Latin American Cohort
Manuel Ugarte-Gil, Lima, Peru

P5.94 Diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE). Analysis of 78 cases
Marco Martinez-Martinez, San Luis Potosi, Mexico

P5.95 Increased Short Term Adverse Events After Total Hip and Total Knee Arthroplasty
Susan Goodman, New York, United States

P5.96 Factors associated with early damage accrual in patients with Systemic Lupus Erythematosus: 12-month preliminary results from the inception cohort of the multicenter Early Lupus Project
Matteo Piga, Monserrato, Italy

P5.97 Gender influences the clinical course of lupus erythematosus (LE) - a retrospective cohort study
Barbara Böckle, Innsbruck, Austria

P5.98 Disease activity patterns over time in patients with SLE - A retrospective descriptive analysis of the Hopkins Lupus Cohort
Noémi Györi, Stockholm, Sweden

P5.99 How good a job are we Rheumatologists doing in screening for Hepatitis B and C before initiating Immunosuppressive/s in SLE?
Meenakshi Jolly, Chicago, IL, United States

P5.100 Minorities with Lupus Nephritis and Medications: A study of Facilitators to Medication Decision-Making
Jasvinder Singh, Birmingham, AL, United States

P5.101 Chronic daily headache in Korean patients with systemic lupus erythematosus
Chang-Nam Son, Daegu, Republic of Korea

P5.102 Anti-C reactive protein antibodies in Korean patients with systemic lupus erythematosus
Chang-Nam Son, Daegu, Republic of Korea

P5.103 Expression of serum B cell activating factor from the tumor necrosis factor family (BAFF) in systemic lupus erythematosus (SLE): relationship with disease features
Tatiana Panafidina, Moscow, Russian Federation

P5.104 Malignancy Risk In Systemic Lupus Erythematosus Patients Treated With Cyclophosphamide
Neslihan Yilmaz, Istanbul, Turkey

P5.105 Factors associated with recognition of depression by healthcare providers in systemic lupus erythematosus
Cristina Drenkard, Atlanta, GA, United States
**P5.106**
The association of systemic lupus erythematosus with risk of osteonecrosis - a Danish nationwide population-based case-control study
Alina Dima, Bucharest, Romania

**P06 Antiphospholipid syndrome**
P6.02
Does Anti-DNA positivity increase the incidence of secondary antiphospholipid syndrome in lupus patients?
Sherif Sherif, Cairo, Egypt

P6.03
Serum coagulation markers and cerebral MRI in lupus patients with antiphospholipid antibodies and cognitive dysfunction
Seamus O’Byrne, Hamilton, Canada

P6.04
Risk of antiphospholipid nephropathy in renal transplanted lupus patients treated with mTORC inhibitors
Carolina Sánchez-Marcos, Barcelona, Spain

P6.05
Clinical and immunological correlations in patients with antiphospholipid syndrome
Nikolay Stoilov, Sofia, Bulgaria

**P07 Pediatric lupus**
P7.01
Epstein Barr virus immune response, viral load and association with disease activity in paediatric systemic lupus erythematosus patients
Anita Rana, Chandigarh, India

P7.02
Effects of rituximab therapy in 9 children with refractory systemic lupus erythematosus and ANCA positive vasculitis - single centre experience
Marija Jelušić, Zagreb, Croatia

P7.03
The long-term outcome of alveolar hemorrhage in juvenile systemic lupus erythematosus: a report of five Saudi children
Wafaa suwairi, Riyadh, Saudi Arabia

P7.04
Juvenile Systemic Lupus Erythematosus (JSLE) activity at diagnosis and organ damage during follow-up
Angela Mosquera, Bogota, Colombia

P7.05
Differences in clinical features and mortality between childhood-onset and adult-onset systemic lupus erythematosus: prospective single-center cohort study
Young Bin Joo, Seoul, Korea, Republic of

P7.06
Digital vasculitis survey in 852 childhood-onset systemic lupus erythematosus patients: a multicenter cohort study
Ana Sakamoto, São Paulo, Brazil

P7.07
Chronic arthritis survey in 852 childhood-onset systemic lupus erythematosus patients: a multicenter cohort study
Ana Sakamoto, São Paulo, Brazil

P7.08
Validating the Pediatric Automated Neuropsychological Assessment Metrics Cognitive Performance Scores in the screening of neurocognitive impairment in childhood-onset systemic lupus erythematosus
Deborah Levy, Toronto, Canada

P7.09
PKCd at the gate of autoimmunity: B cell deficiency and severe autoimmunity caused by deficiency of protein kinase C delta
Elisabeth Salzer, Vienna, Austria

P7.11
The CHILL-NL study, very long term outcome of childhood-onset SLE: Education and Work participation
Anne Kardolus, Rotterdam, Netherlands

P7.12
The CHILL-NL study, very long-term outcome of childhood-onset SLE: disease activity, damage, quality of life and fecundity
Noortje Groot, Rotterdam, Netherlands

P7.13
IL-6 and IL-10 levels in childhood-onset systemic lupus erythematosus: are they different in the active and inactive forms of the disease?
André Cavalcanti, Recife, Brazil

P7.14
Cyclophosphamide use in Juvenile Systemic Lupus Erythematosus (JSLE) in a tertiary care center in Saudi Arabia, a retrospective study
Abdullah Al-Sonbul, Riyadh, Saudi Arabia

P7.15
Long-term outcomes of diffuse proliferative lupus nephritis and the significance of global and segmental subclasses in children
Pornpimol Rianthavorn, Pathumwan, Thailand

P7.17
Advanced Proteomics for Lupus Nephritis Biomarker Discovery
Ashwaq AlEed, Buraidah, Saudi Arabia

P7.18
Rituximab therapy in neuropsychiatric manifestations of juvenile systemic lupus erythematosus
Inês Madureira, Lisboa, Portugal

**P08 Miscellaneous**
P8.01
Identification of a systemic lupus erythematosus risk locus spanning the genes ATG16L2, FCHSD2, and P2RY2 in Koreans
Christopher Lessard, Oklahoma City, United States

P8.02
Genome-wide analysis of DNA methylation in systemic lupus erythematosus
Johanna Sandling, Uppsala, Sweden

P8.03
The role of musculoskeletal ultrasound in the stratification of SLE; a multicenter crosssectional study
Ahmed Zayat, Leeds, United Kingdom
P8.04 An explanation for the failure of whole blood interferon signatures to represent SLE disease activity
Yasser El-Sherbiny, Leeds, United Kingdom

P8.05 Comparison of discoid versus subacute cutaneous lupus reveals overlapping and distinct interferon regulated pathways
J. Michelle Kahlenberg, Ann Arbor, United States

P8.06 Thrombotic thrombocytopenic purpura in patients from the Systemic Lupus Erythematosus registry of the Spanish Society of Rheumatology (RELESSER)
Ana Lois Iglesias, A Coruña, Spain

P8.07 Lupus like glomerular disease associated with Human Immunodeficiency Virus (HIV) in the era of highly effective antiretroviral therapy (HAART) in a high complexity university hospital between the years of 2006 and 2012
Fernando Vela-Lozada, Bogota, Colombia

P8.08 New classification criteria for systemic lupus erythematosus correlate with disease activity
Felina Anić, Rijeka, Croatia

P8.09 Urinary concentrations of chemokines and cytokines in lupus patients
Kok-Yong Fong, Singapore, Singapore

P8.10 Both contact system and neutrophil extracellular traps take part in the pathogenesis of lupus nephritis
Guang-qun Xing, Qingdao, China

P8.11 Level and significance of serum peptidylarginine deiminase type 4 in patients with systemic lupus erythematosus
Guang-qun Xing, Qingdao, China

P8.12 Changes in the monocyte subsets phenotype are associated with HMGB1+ microparticles isolated from Systemic Lupus Erythematosus patients
Diana Castaño, Medellin, Colombia

P8.13 Ki-67 proliferation index in renal biopsy samples of patients with systemic lupus erythematosus
Ediz Dalkılıç, Bursa, Turkey

P8.14 Activity and damage in systemic lupus erythematosus patients during follow-up period
Tatiana Reshetnyak, Moscow, Russian Federation

P8.15 At pre-clinical stage; connective tissue disease is indistinguishable from other inflammatory arthritis on ultrasound in CCP-negative early arthritis patients
Ahmed Zayat, Leeds, United Kingdom

P8.16 Profile of male Systemic Lupus Erythematosus observed in Internal Medicine
Djanette Hakem, Algiers City, Algeria

P8.17 The association between type I Interferon Response, complement activation and clinical findings in Systemic Lupus Erythematosus
Omer Pamuk, Edirne, Turkey

P8.18 Increased serum Tie-2 Level in Systemic Lupus Erythematosus patients and related factors
Omer Pamuk, Edirne, Turkey

P8.19 Description of Vitamin D enzymatic machinery in Systemic Lupus Erythematosus
Ioana Saulescu, Bucharest, Romania

P8.20 Associations of SNPs located in STAT4, TNXB and ITGAM genes with susceptibility to Discoid and Systemic Lupus Erythematosus
Katarzyna Skonieczna, Bydgoszcz, Poland

P8.21 Factors implicated in development of atherosclerotic plaque in SLE
Mirela Parvu, Targu Mures, Romania

P8.22 Jessner lymphocytic infiltration of the skin or lupus erythematosus?
Panagiotis Athanassiou, Thessaloniki, Greece

P8.23 The cardiovascular risk associates in systemic lupus erythematosus patients
Alina Dima, Bucharest, Romania

P8.24 Renal biopsy complications in patients diagnosed with Lupus Nephritis - experience of a Portuguese Rheumatology Center
Ana Águeda, Aveiro, Portugal

P8.25 Unusual Manifestations of SLE Observed in Internal Medicine Cohort
Djanette Hakem, Algiers City, Algeria

P8.26 Capabilities of European lupus Groups: members of LUPUS EUROPE
Kirsten Lerstrøm, Romford, United Kingdom

P8.27 Are vitamin D levels in lupus patients associated with non-scarring alopecia?
Baris Gundogdu, Mardin, Turkey

P8.27 Are vitamin D levels in lupus patients associated with non-scarring alopecia?
Baris Gundogdu, Mardin, Turkey

P8.28 Hair mercury is inversely related to disease associated damage in systemic lupus erythematosus
William Crowe, Belfast, United Kingdom

P8.29 Another image of lupus in men
Daniela Manuela Popescu, Targu Mures, Romania
P8.31
The carotid intima-media thickness- role of assessment clinically silent atherosclerosis in patients with on long-term corticosteroid treatment
Velichka Popova, Plovdiv, Bulgaria

P8.32
Comparison of the responsiveness and minimal important differences (mid) of the lupusqol and the SF-36 in patients with Systemic Lupus Erythematosus (SLE) after treatment of a moderate or severe flare
Lee-Suan Teh, Blackburn, United Kingdom

P8.33
Pattern of Lupus Nephritis in the Military Hospital: A histological and immunofluorescence study
Naffesa Al sheikh, Khartoum, Sudan
Information for Presenters

PUBLICATION
All submitted abstracts (invited and submitted talks) will be published in Clinical and Experimental Rheumatology.

POSTER PRESENTATIONS
Schedule for display, mounting and removal
- Posters will be on display from Wednesday, September 2 to Saturday, September 5
- Poster mounting will be possible from: Wednesday, September 2 onwards
- Posters must be mounted before Friday, September 4, 8.00 a.m. for “early bird poster viewing without presenters”
- Removal will be possible on: Saturday, September 5 from 15:15 hrs – 18:30 hrs strict!
  Access after this time is not possible!
Please note that posters not removed until then, will be taken down and discarded.

Presence at Posters
In order to enable discussion and interaction with other participants, you (or one of your group) are kindly requested to be present at your poster board of you or one of your group will be mandatory between:
- 14:15 hrs – 15:15 hrs on Friday, September 4 for posters topics 1 to 5
- 14:15 hrs – 15:15 hrs on Saturday, September 5 for posters topics 5 to 8

Format
- Only posters in portrait format can be mounted.
- The usable surface on the poster board will be 90 cm width x 150 cm height (approx. 35 x 59 inches).
- Only adhesive tape can be used to mount posters. Material will be made available onsite.

Important Guidelines
- Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the poster.
- When presenting data and health information (including photos) all presenters must have consent from human subjects and comply with applicable regulations.
- Posters should stimulate discussion. Therefore, keep text to a minimum, emphasize on graphics and make sure every item is necessary.
- Include the title of your presentation. The abstract titles will not be displayed on the boards provided.
- The lettering of the poster header should be at least 2.5 cm high. Detailed information should be provided in a smaller type, but remember that your text must be easily readable from distances of at least 1 meter.
- Optional Materials: If you wish, you may prepare handouts for distribution to interested colleagues. Alternatively you may include a QR code on the poster which would trigger a download of the handouts (WIFI is available in the poster area). Some authors may also wish to provide business cards/contact information. Your passport photograph on the poster may facilitate contacts during the congress.
- For additional assistance in preparing your poster, there are a number of excellent resources available online. For more information, type “scientific poster preparation guidelines” into your internet search engine.

ORAL PRESENTATIONS
Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion. Please rehearse your talk to make sure it will fit comfortably into the available time. Please note that, as a rule, presenters can show a (final) slide with all acknowledgements, however, in view of the short time available, names cannot be read to the audience.

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.
A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.
If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

Projection and Technical Setting
- All rooms will be equipped with data-projection (no slides).
- The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Should you absolutely have to use your own laptop or notebook, please contact the congress office in advance.
- Please bring a USB-stick, CD-ROM or floppy disk all formatted for Windows® (PC). You may want to carry a second disk/CD as a back-up in case there is any insoluble technical problem.
- File Format: Microsoft® Power Point® presentation formatted for Windows® (PC) only. (Operating system: Windows XP®)
- Preferred Resolution: XGA (1024 x 768 pixel)
### Registration Fees (in EUR)

<table>
<thead>
<tr>
<th></th>
<th>Early Bird until May 3, 2015</th>
<th>From May 4 to Aug. 15, 2015</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegate</td>
<td>490</td>
<td>550</td>
<td>610</td>
</tr>
<tr>
<td>Trainee ¹</td>
<td>200</td>
<td>235</td>
<td>280</td>
</tr>
<tr>
<td>Allied Health Care Professionals</td>
<td>200</td>
<td>235</td>
<td>280</td>
</tr>
<tr>
<td>Patients’ Delegates ² / PARE ³</td>
<td>50</td>
<td>60</td>
<td>80</td>
</tr>
<tr>
<td>Session “Meet the Professor 1-8” ⁴</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Session “Immunology for MDs”</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Networking Reception for participants</td>
<td>No Fee, but registration is mandatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Press/Media Pass</td>
<td>No fee - Upload of Press ID card mandatory</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ The Trainee registration is available for “Clinicians in Training” and “non Tenured Scientists” (scientist not being professor or associate professor) under 35 years of age. A letter of confirmation of your status from the Head of Unit or Institute must accompany the formal registration form.

² By registering as patient’s delegate, you acknowledge that you are not allowed to enter the exhibition area of the pharmaceutical industry.

³ Representatives of national PARE organisations.

⁴ Meet the professor sessions 1-4 will take place on Thursday, September 3 and Meet the professor sessions 5-8 will take place on Friday, September 4.

### WHAT IS COVERED BY THE REGISTRATION FEES?

- Admission to all scientific sessions
- Abstract book and programme, bag, …
- Welcome Reception
- Mayor’s Reception (registration mandatory)
- Coffee breaks
- Farewell Reception
- Admission to exhibition
- Ticket for Public Transportation

### IMPORTANT

The reduced registration fee is only applicable, if it has been credited to the congress account before the respective deadlines. Registering before the respective deadlines without performing an actual payment is not sufficient to benefit from the reduction.

Payments onsite are possible made in cash (in EURO) or by credit card (Diners Club, Mastercard and Visa). No other credit cards are accepted.

### OPENING HOURS REGISTRATION DESK

- Wednesday, September 2, 2015: 12.00 – 19.00 hrs
- Thursday, September 3, 2015: 07.00 – 18.30 hrs
- Friday, September 4, 2015: 07.30 – 19.30 hrs
- Saturday, September 5, 2015: 07.45 – 18.00 hrs
**Wednesday, September 2, 2015**  
**Welcome Reception at the Hofburg Congress Center**  
(for registered participants)  
After the Opening Ceremony, you will be served refreshments and fingerfood in the exhibition area of the congress center. Registration is mandatory!

**Thursday, September 3, 2015**  
**Mayor's Reception – The Mayor of the City of Vienna is pleased to invite you to a Cocktail Reception at the Vienna City Hall**  
(for registered participants – no fee, but registration is mandatory!)  
Meet your colleagues at the City Hall and enjoy the evening with a buffet and live music. Registration is mandatory in order to receive a ticket. Limited number of tickets handed out on a first come, first served basis. Dress code: smart casual

**Saturday, September 5, 2015**  
**Farewell Reception at the Hofburg Congress Center**  
(for registered participants)  
After the last Session, you will be served Sausages & Beer in the exhibition area of the congress center.

---

Scientific session 15 ("Focus on patient reported outcomes") has been arranged by the Organizing Committee with support from UCB.

UCB had no influence on the selection of topics or speakers which was under the sole responsibility of the Committee.
BADGES
Participants should collect name badges from the conference registration desk. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue. Exhibitors will also receive badges to allow access to the respective areas. Lost badges can be replaced at the registration desk. However, a handling fee of EURO 30.- will be charged.

BANK SERVICES - MONEY MATTERS
Banks are open from 8.30 – 12:30 and from 13:30 – 15:00, Monday to Friday. Some banks are also open on Thursday afternoons until 17:30 hrs. Cash machines (ATMs), which accept all major international bank cards, are available throughout the city. The currency of Austria is the Euro (€). Major credit cards are widely accepted, but please always check beforehand.

CAR PARKING
A very limited number of parking slots will be made available on a first come, first served basis directly in front of the HOFBURG Congress Center. However, please be aware that if you park on a reserved parking space, your car will be almost immediately towed away. Parking garages are also available around the conference center – please ask at the general information desk for directions.

CERTIFICATE OF ATTENDANCE
The certificates of attendance are issued at the registration desk. You will receive it at the same time as you register or pick-up your registration material. If you need an additional “confirmation of poster presentation” or “confirmation of oral presentation”, please inform the registration desk manager who will have it prepared for pick-up at the agreed time.

CHILDREN AND ACCOMPANYING PERSONS
Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the LUPUS 2015 congress asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the congress center they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of the public is invited to participate in the LUPUS 2015 Congress scientific programme, they should be accompanied by a qualified healthcare professional or a LUPUS 2015 representative observing the LUPUS 2015 restrictions where appropriate.
CANCELLATIONS AND REFUNDS
Please note that only written cancellations addressed to
LUPUS 2015 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria
either per E-Mail: lupus2015@medacad.org or Fax: +43 1 407 82 74 could be accepted.
The following rules apply:
- before June 30, 2015: 50% refund
- after June 30, 2015: no refund

CLOAKROOM AND LUGGAGE
A cloakroom and luggage storage facilities are available in the congress venue.

CME CREDITS (DFP Punkte)
The 11th International Congress on Systemic Lupus Erythematosus has been granted 20 European CME credits (ECMEC).
EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.
The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COFFEE BREAKS
During the session breaks refreshments (coffee, tea, water and biscuits&cookies) will be served free of charge to participants wearing name badges. Coffee breaks will take place in the exhibition and poster areas.

CONFERENCE VENUE
HOFBURG Vienna Congress Center
Heldenplatz, Vienna, Austria
www.hofburg.com
CURRENCY
The official currency of Austria is the Euro (€). 1 EURO = 1.09 USD = 0.70 GBP = 136.41 JPY = 1.07 CHF = 6.79 CNY (as per date of printing)

DRINKING WATER
Tap water in Austria is of very good quality and can be used without concern.

ELECTRICITY SUPPLY
220V - 50Hz AC. Adaptors can be obtained from your hotel reception or electronics stores.

EMERGENCY PHONE NUMBER
The phone number to dial for emergencies is 112.

EXHIBITION HOURS:
Wednesday September 2, 2015  16.00 – 21:00
Thursday, September 3, 2015  08.00 – 17.00
Friday, September 4, 2015  08.00 – 17.30
Saturday, September 5, 2015  08.00 – 19.30

INTERNET
Free WIFI will be available troughout the congress center.

INSURANCE
In registering for the LUPUS 2015 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and insurance.

LANGUAGE
The official language of the congress is English (no simultaneous translation provided).

LUNCHES
The congress will not serve lunch. Lunchboxes will possibly be served at some satellite symposia organised by the sponsoring companies. A cash bar will be available in the Hofburg Lounge on the first floor.

MESSAGE BOARD
A message board will be available in the registration area.

OPENING HOURS REGISTRATION DESK
Wednesday, September 2, 2015:  12.00 – 19.00 hrs
Thursday, September 3, 2015:  07.00 – 18.30 hrs
Friday, September 4, 2015:  07.30 – 19.30 hrs
Saturday, September 5, 2015:  07.45 – 18.00 hrs

PROGRAMME CHANGES
The organiser cannot assume any liability for changes in the programme due to external or unforeseen circumstances.

TELEPHONE
For international calls to Austria, dial the international code (+43) and the correspondent’s number without the 0. For international calls from Austria, dial your correspondent's international code and number.

POSTER REMOVAL
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that will not be removed by Saturday, September 5, 2015, 18.30 hrs, will be removed by the staff and will not be kept or mailed to the author after the meeting, but will be discarded.

PROGRAMME CHANGES – ACCESS TO SESSIONS
The conference organisers reserve the right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.

STAFF
Should you have any questions, congress staff will be pleased to help you. Please contact the registration desk.

TAXIS IN VIENNA
If you do not wish to use the public transport, you can also use one of the numerous taxis waiting at one of the taxi stands or simply hire one on the street. If you wish to call a taxi the following numbers will connect you to the Taxi services in and around Vienna: (0043) 1 60160 or (0043) 1 40100 or (0043) 1 31300.
TICKETS FOR PUBLIC TRANSPORTATION
Tickets for Public Transportation will be offered free of charge to registered participants and will be valid throughout the congress days. Tickets can be collected at the Bags Desk with the respective voucher you will receive upon registration on site.

TOURIST INFORMATION
The nearest tourist information point to the congress center is located in the 1st district in the city center: Albertinaplatz, corner of Maysedergasse 1010 Vienna. It is open daily from 09:00hrs to 19:00hrs
www.wien.info

TRAVELLING TO THE HOFBURG CONGRESS CENTER BY PUBLIC TRANSPORT
The Hofburg is located in the centre of the Old Town and can easily be reached with public transport. Two underground stations, and bus and tram stops are within walking distance.
Underground line U3: station “Herrengasse”, walk to Hofburg 5 min
Tramway lines 1, 2 or D: station “Burgring”, walk to Hofburg 3 min
City Bus 2A: bus stop “Heldenplatz”, walk to Hofburg 3 min

V.A.T.
A value-added tax (V.A.T.) of 10% (food) to 20% (other items) is applied to all products and services. In most cases it is included in the price. Whenever it is not included, however, it will be clearly specified.

WIFI
Wifi is available throughout the conference venue. Network ID: LUPUS2015, password: lupus2015
Satellite Symposium

The Lupus Trial in 2020: What might the outcome measures be?

Thursday, September 3, 2015
13:15 – 14:15 hrs
Festsaal, HOFBURG Vienna Congress Center, Heldenplatz, Vienna, Austria

Symposium Agenda

Moderator: Marta Mosca

- “The Evolution of the Composite Responder Index”
  Professor Richard Furie (New York, USA)

- “Optimal use of what is currently available.”
  William W. Freimuth, M.D., Ph.D. Vice President, Proof of Concept Clinical Head, Pfizer Inc.

- “The future of the lupus trial”
  Professor Ronald van Vollenhoven (Stockholm, Sweden)

- Q&A – Panel discussion
GSK Satellite Symposium at LUPUS 2015

11th International Congress on Systemic Lupus Erythematosus
The strengths and limitations of current SLE therapies: What does the evidence tell us?
Friday 4th September 2015, 12:45–14:15
Festsaal, HOFBURG Vienna Congress Center, Heldenplatz, Vienna, Austria

Symposium Agenda

<table>
<thead>
<tr>
<th>Timings</th>
<th>Presentation title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45–13:00</td>
<td>What does treatment success look like in SLE?</td>
<td>Chairman</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eric Morand</td>
</tr>
<tr>
<td>13:00–13:25</td>
<td>What has experience taught us about the strengths and limitations of conventional therapies?</td>
<td>Debate faculty:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Strengths: George Bertsias</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limitations: Eric Morand</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Audience Q&amp;A and faculty discussion</td>
</tr>
<tr>
<td>13:25–13:55</td>
<td>What has experience taught us about the strengths and limitations of biological therapies?</td>
<td>Debate faculty:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Strengths: Ronald van Vollenhoven</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limitations: Morton Scheinberg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Audience Q&amp;A and faculty discussion</td>
</tr>
<tr>
<td>13:55–14:10</td>
<td>Audience Q&amp;A</td>
<td>All faculty</td>
</tr>
<tr>
<td>14:10–14:15</td>
<td>Summary and closing statement</td>
<td>Chairman</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eric Morand</td>
</tr>
</tbody>
</table>

Symposium Objectives and Key Topics

- What does treatment success look like in SLE?
  - Discuss disease characteristics, short-term treatment goals and/or treatment outcomes associated with best long-term prognosis in SLE
  - Translate the published findings into the language used by practicing physicians (e.g. organ specific manifestations) and what treatment success should look like in SLE

- What has experience taught us about the strengths and limitations of conventional therapies?
  - Brief overview of the conventional therapeutic approach to SLE management
  - Explore the potential clinical benefits of conventional therapies in SLE
  - Discuss important safety considerations when combining standard of care (SoC) treatments in patients with SLE

- What has experience taught us about the strengths and limitations of biological therapies?
  - Explore the strengths and limitations of biological therapies in SLE when managing patients whose disease is not adequately controlled by SoC
  - Discuss important safety considerations when combining SoC and biologics in patients with SLE
Saturday 5th September 12.45-2.00pm
Festsaal, Hofburg Vienna Congress Center

Faculty and Program

Symposium Chair: Prim Univ. Prof. Dr. Josef Smolen

12.45-1.00
Perspective on lupus research
Josef Smolen, MD
Division of Rheumatology, Medical University of Vienna, Austria

1.00-1.20
Optimizing clinical trial designs in systemic lupus erythematosus (SLE) and lupus nephritis (LN)
Ronald van Vollenhoven, MD, PhD
Rheumatology Unit, Department of Medicine
Karolinska University, Stockholm, Sweden

1.20-1.40
Choosing the right patient population in SLE and LN: critical view on biomarkers
Betty Diamond, MD, PhD
Feinstein Institute for Medical Research, New York, US

1.40-2.00
Panel discussion
Faculty-All
The LUPUS 2015 Congress gratefully acknowledges the support of the following institutions, companies and organisations
(as per date of printing August 2015)

PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSORS

UNRESTRICTED EDUCATIONAL GRANTS
Map Public Transport

ENTRANCE
Hofburg Vienna Congress Center
Heldenplatz, Vienna